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Aberrant epigenetic alterations in the genome are believed to be a potential 
cause of some forms of cancer. Due to their reversibility, epigenetic modifications are 
considered potentially useful in drug development (epi-drugs). Currently available 
synthetic epi-drugs have many adverse effects. Epigenetic pathways may represent 
targets for natural product utilized in cancer treatment. The present study was designed 
to evaluate the efficacy of a traditionally used product, wild yam root extract (WYRE), as 
a potential demethylating agent in breast cancer.  Two breast cancer cell lines were 
used, MCF-7 (estrogen receptor positive, ER+) and MDA-MB-231 (ER negative, ER-), 
and the effect of WYRE on a gene, GATA3, a potential marker of breast cancer 
development was studied. GATA3 expression is controlled by methylation, and it is 
found to be expressed higher in ER+ cells with correlating promoter hypomethylation, 
and its expression is insignificant in ER- cells correlating with promoter 
hypermethylation. In the current study, cells were treated with WYRE (0-50 μg/mL) for 
72h and then evaluated for changes in mRNA and in promoter methylation patterns. 
WYRE significantly reduced cell proliferation of both cell lines and increased 
transcription of GATA3 and methylating DNMT proteins (DNMT1, 3A, and 3B) in a 
concentration-dependent manner. Global DNA methylation as analyzed by 5'-methyl-2'-
deoxycytidine (5-mC) and 5-hydroxymethylcytosine (5-hmC) showed that 5-mC was 
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increased in MCF-7, whereas 5-hmC level was reduced in MDA-MB-231 cells. Since 5-
hmC is generated from 5-mC by ten-eleven-translocation (TET) enzymes, their 
expression was examined as well following WYRE treatment. Of the TET proteins only 
TET3 mRNA expression was increased by WYRE (50 μg/mL) in MDA-MB-231 cells; no 
changes were noted in MCF-7 cells. Methylation analysis of the GATA3 promoter 
indicated demethylating activity of WYRE in MDA-MB-231 cells. Two compound isolates 
from WYRE considered responsible for the anti-cancer activity, dioscin and diosgenin, 
were also evaluated as described above for the root extract. Both dioscin and diosgenin 
were able to reduce in vitro cell viability of both ER+ (MCF-7) and ER (MDA-MB-231) 
human breast cancer cells, with dioscin demonstrating greater potentcy than diosgenin 
in both cell lines. Dioscin at 5.76 µM showed upregulation of GATA3 mRNA expression 
in MDA-MB-231 cell only. GATA3 protein expression was also enhanced in a 
concentration- dependent manner in MDA-MB-231 cells treated with dioscin (0-5.76 µM) 
as seen by both western blot, and by immunocytochemistry followed by confocal 
microscopy. Interestingly, dioscin was founded to enhance the expression of GATA3 
protein in both cell lines. Despite increased transcription in the MDA-MB-231 cells, an 
upstream (ZFPM2) and downstream (E-cadherin) markers of GATA3 function were 
examined. ZFPM2 mRNA expression significantly increased by dioscin at 5.76 µM in 
both cell lines, as did E-cadherin expression. Other cell transition markers were studied, 
such as MMP9 and VIM. We found that dioscin at 2.30 µM decreased expression of 
MMP9 transcription, and at 2.30 and 5.76 µM suppressed VIM mRNA expression in 
 iv 
MDA-MB-231 cells. Notably, dioscin was found to have an inhibitory effect on migration 
of MDA-MB-231 cells in concentration- and time- dependent manner, as observed by a 
wound-healing assay and in migration/invasion assay in both breast cancer cell lines. 
These findings reveal a new therapeutic potential for anti-metastatic therapy targeting 
epigenome and in the future these plant extract as a whole or dioscin may be able to 
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Breast cancer accounts for ∼30% of all cancers diagnosed in the United States, 
and it is the second leading cause of cancer death in women (Ordway et al. 2007, 
Society 2014). Overall, women have a >10% lifetime risk of developing invasive breast 
cancer and the risk increase with age; breast cancer accounts for 1% of all male 
cancers (Feuer et al. 1993, Lin et al. 2010). Mammary gland development initiates 
during fetal development and continues postnatally through puberty, pregnancy, 
lactation, and subsequent involution during which the gland undergoes extensive 
morphological and functional changes (Muller et al. 2006). The development of cancer 
in the breast is a stepwise process that begins in mammary ducts and progress through 
five stages (0-4). The American Joint Committee on Cancer (AJCC) has designated 
staging based on tumor size, the degree of lymph node involvement, the presence of 
inflammatory signs, and evidence of metastasis.  Stage 0 is used to describe non-
invasive breast cancers, such as DCIS (ductal carcinoma in situ) where there all 
evidence of cancer cells or non-cancerous abnormal cells is locally contained. Stage 1,
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tumors are less than 2 cm, noninvasive, and growth of the cells does not affect the 
functions of neighboring cells and tissues. Stage 2, the tumor size is between 2 and 5 
cm and becomes invasive and begins to affect axillary nodes but does not reach any 
neighboring tissues. Stage 3, tumor cells in the individual lymph nodes begin clumping 
together and cause inflammation. The tumor size is greater than 5 cm or axillary lymph 
node fixed to each other or other structures. The fourth stage breast cancer 
metastasizes to other distant organs most often the brain, lung, or liver. (Agrawal et al. 
2006, Institution)  
There are many risk factors proposed for breast cancer development that include 
individual genetic background, pregnancy, and lifestyle elements, such as diet and 
environment. Although extensive research has been done, the causes and mechanisms 
of breast cancer development and progression are complex and still remain 
inconclusive (Cebrian et al. 2006, Veeck and Esteller 2010). Estrogen both from 
endogenous and exogenous sources and their receptors have a proliferative effect on 
mammary gland epithelium; estrogens may increase susceptibility to environmental 
carcinogens, oxidative catabolism of estrogens generate reactive oxygen species (ROS) 
that cause genetic damage. Mutations of BRCA1 and BRCA2 and other related genes 
such as p53, Bcl-2, Her2, or c-Myc can be significant for breast cancer development 
(McCance et al. 2010). Breast carcinogenesis involves not only uncontrolled 
proliferation, but also alterations in cell signaling pathways as well as aberrant or loss of 
apoptosis as a consequence of accumulated genetic alteration (McCance et al. 2010). 
Even though the mechanisms associated with breast cancer are genetic alterations, 
including specific gene amplifications, deletions, point mutations, chromosome 
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rearrangements, and aneuploidy like other types of cancers, it is also driven by 
epigenetic mechanisms. (Dworkin, Huang, and Toland 2009a, Lo and Sukumar 2008, 
Jovanovic et al. 2010, Kress et al. 2010)  
 
Epigenetics  
The term epigenetics is defined as heritable changes in gene expression that do 
not involve DNA nucleotide sequences (Jones and Laird 1999, Yoo and Jones 2006). It 
is the “stable alterations in gene expression potential that arise during development and 
proliferation” (Jaenisch and Bird 2003). Furthermore, epigenetics is also defined as “the 
manifestation of a phenotype, which can be transmitted to the next generation of cells or 
individuals, without alteration of the DNA sequence (genotype)” (Devinoy and Rijnkels 
2010). In general, epigenetics has been interpreted more widely to include any external 
effect on the phenotype. Epigenetic therapy is a new and rapidly developing area and a 
potentially useful form of therapy in breast cancer  due to the fact that epigenetic 
defects mostly occur at the  chromosomal level in transformed cells and are thought to 
be more easily reversible in comparison with genetic defects (Kristensen, Nielsen, and 
Hansen 2009). At the biochemical level, the epigenetic alteration in chromatin 
conformation involves DNA methylation, several forms of histone modifications, and 
microRNA (miRNA) expression. These events modulate chromatin structure and in turn 
activate or silence gene expression (Lo and Sukumar 2008, Lustberg and Ramaswamy 
2009). The understanding of these epigenetic changes and their contributions to 
carcinogenesis is very important for further progress in the field of diagnosis, prognosis, 
4 
 
and therapy of any cancer including breast cancer. 
Epigenetic Mechanisms  
1. Histone Modification 
 
One of the epigenetic mechanisms influencing gene transcription is histone 
modification. Histone proteins are responsible for maintaining chromatin structure either 
in an accessible or inaccessible state to various transcriptional activators and 
repressors for their binding to gene promoters (Dhalluin et al. 1999). The nucleosomes 
of euchromatic DNA contain an octamer of four core histones (H2A, H2B, H3, and H4) 
around which 146 bp of DNA are wrapped (Davis and Ross 2007, Ito and Adcock 2002, 
Luger et al. 1997, Minard, Jain, and Barton 2009, Strahl and Allis 2000). Histones can 
be modified post-translationally by acetylation, methylation, phosphorylation, 
sumoylation, ubiquitination, ADP ribosylation, deamination, proline isomerization, and 
newly identified propionylation (Liu et al. 2009, Schubeler et al. 2004, Shilatifard 2006) 
and all these effects can alter the accessibility of DNA to transcriptional activity. Most of 
these modifications are reversible (Davis and Ross 2007). Moreover, gene repression or 
activation by histone acetylation or methylation is dependent on the specific residues. 
The most important histone modifications, having effects on gene expression, are 
located on histone H3 and histone H4 (Bronner et al. 2010). One of them, known to 
have a gene silencing role and to have a strong relationship with DNA methylation, is 
the di or trimethylation of lysine 9 of histone 3 (H3K9me2 or H3K9me3). But methylation 
on the same histone on lysine 4 (H3K4me) is related to gene activation. All these 
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modifications are catalyzed by specific enzymes (Peterson and Laniel 2004, Sims and 
Reinberg 2006, Lo and Sukumar 2008).  Acetylation of histones occurs within the 
amino-terminal tails protruding from the surface of the nucleosomes and also on the 
globular core region by transfer of acetyl group from acetyl-CoA to the ε amino group of 
lysine residues (Nε). The reaction is catalyzed by histone acetyl transferase (HAT). The 
global acetylation of histone tails decreases electrostatic interactions between the 
negatively charged DNA and the basic lysine residues (Travers and Thompson 2004). 
As a result, the chromatin becomes more open to provide access for transcription 
factors to DNA. Conversely, deacetylation, which is catalyzed by histone deacetylases 
(HDACs), removes the neutralizing acetyl charge and induces chromatin condensation 









Figure 1: Schematic representation of histone modification (acetylation and 
deacetylation). HATs induce relaxed chromatin which allows access to the various 
transcriptional factors associated with gene activation (gene switched on). HDACs 
induce closed chromatin associated with gene repression (gene switched off). HAT= 





Moreover, HATs also acetylate several nonhistone proteins such as GATA1, E2F1, pRB, 
or TP53 frequently associated with cellular transformation (Martinez-Balbas et al. 2000). 
HATs cannot bind to target gene promoters directly but rather are recruited by DNA-
bound transcription factors (Roth, Denu, and Allis 2001). However, HDACs whose 
primary role is to oppose the activity of HATs are recruited to the hypermethylated CpG 
islands of tumor suppressor genes via Methyl-CpG-binding Domain (MBDs) or 
independently of methylation by specific transcription factors (Deckert and Struhl 2001). 
Many nonhistone proteins are also used as substrates for HDACs (Deckert and Struhl 
2001, Gray and Ekstrom 2001, McLaughlin and La Thangue 2004, Robertson et al. 
2000). HATs can be classified into five families: the GNAT family, the MYST family, the 
p300/CBP family, the SRC family, and the TAFII250 family (Suzuki and Miyata 2006, 
Roth, Denu, and Allis 2001). Until now, 18 human HDACs have been identified and are 
grouped into four classes, Classes I, II, III, and IV, based on their homology with yeast 
HDACs and their phylogenetic conservation (Gregoretti, Lee, and Goodson 2004). 
Histone methylation occurs in lysine and arginine residues, catalyzed by histone lysine 
methyl transferases (lysine) or histone arginine methyl transferases (arginie) (Yamane 
et al. 2007). At present, there are 24 known sites of methylation of histones: 17 are 
lysine residues, and 7 are arginine residues (Bannister and Kouzarides 2005). 
Furthermore, lysine side chains may be mono-, di-, or trimethylated, whereas the 
arginine side chain may be either mono- or dimethylated. In contrast to histone 
acetylation, histone methylation does not change histone’s charge (Dalvai and Bystricky 
2010). Recruitment of specific motif bearing factors to the methylated lysine is 
responsible for affecting chromatin structure. Histone demethylation is catalyzed by 
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histone demethylases (Shi et al. 2004, Tsukada et al. 2006). Thus, HAT and HDAC 
inhibitors could potentially represent new treatment options for cancer (Jovanovic et al. 
2010, Sung et al. 2008, Eliseeva et al. 2007). 
 
Impact of bioactive dietary components on histone modification  
 
Considerable attention has been paid to bioactive dietary components as breast 
cancer preventive agents targeting HAT and HDAC activities. Although direct cancer 
prevention by specific modulators of HAT has not yet been demonstrated (Hauser and 
Jung 2008), several natural products, such as anacardic acid found in cashew 
(Anacardium occidentale), garcinol, a polyisoprenylated benzophenone derivative from 
Garcinia indica, and curcumin from turmeric, have the potential to inhibit p300 and 
p300/CBP associated factor (PCAF) activity (Fu and Kurzrock 2010, Balasubramanyam 
et al. 2003, Balasubramanyam et al. 2004, Varier et al. 2004). EGCG has shown to 
specifically inhibit HAT but not HDAC in B lymphocytes (Choi et al. 2009). S-
allylmercaptocysteine, a compound found in garlic (Allium sativum), is able to induce 
histone acetylation in T47D human breast cancer cells (Lea et al. 2002).  Further 
studies are necessary to evaluate the potency of these bioactive dietary compounds as 
HAT inhibitors in breast cancer models. Currently, a large number of structurally diverse 
HDAC inhibitors have been synthetically developed or purified from natural sources (Lo 
and Sukumar 2008, Meeran, Ahmed, and Tollefsbol 2010).  Among them suberoylanilide 
hydroxamic acid (SAHA or vorinostat) has been approved for treatment of cutaneous T-
cell lymphomas (Mai and Altucci 2009, Marks 2007). HDAC inhibitors are classified into 
four main groups: hydroxamic acids, cyclic peptides, aliphatic acids, and benzamides 
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(Dalvai and Bystricky 2010, Gregoretti, Lee, and Goodson 2004).  Moreover, it was also 
shown that the HDAC inhibitors played different roles in ER+ and ER- breast cancer 
cells (Thomas and Munster 2009). The tea polyphenol EGCG, when applied to MCF-7 
cells (ER+), can decrease hTERT promoter methylation and ablate histone H3Lys9 
acetylation (Berletch et al. 2008). In MDA-MB-231 cells (ER-), EGCG together with 
trichostatin A (TSA) can reactivate ERα expression via remodeling of the chromatin 
structure of the ERα promoter by altering the status of histone acetylation and 
methylation. A decrease in binding of the transcription repressor complex, Rb/p130-E2F 
4/5-HDAC1- SUV39H1-DNMT1, into the regulatory region of ERα promoter by EGCG 
and TSA was also observed (Li et al. 2010). Sulforaphane (SFN) is an isothiocyanate, 
derived from glucoraphanin in broccoli and broccoli sprouts (Meeran, Ahmed, and 
Tollefsbol 2010). Like other isothiocyanates, SFN is metabolized via the mercapturic 
pathway (Nian et al. 2009). A phase I trial of broccoli sprout extracts containing 
glucosinolates and isothiocyanates produced no adverse effects on human volunteers 
(Shapiro et al. 2006). Computer modeling predicted that SFN-cysteine (SFN-Cys) was a 
good fit for the HDAC active site (Nian et al. 2009). Further studies indicate that SFN is 
able to inhibit HDAC activity in human breast cancer cell lines (MDA-MB-231, MDA-MB-
468, MCF-7, and T47D) without altering the acetylation of H3 or H4 (Pledgie-Tracy, 
Sobolewski, and Davidson 2007). In another study, it was documented that SFN 
inhibited HDAC activity in MCF-7 and MDA-MB-231 human breast cancer cells and 
increased the level of active chromatin markers such as acetyl-H3, acetyl-H3K9, and 
acetyl-H4, whereas it decreased the inactive chromatin markers like trimethyl-H3K9 and 
trimethyl-H3K27 and remodeled the chromatin structure of hTERT promoter (Meeran, 
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Ahmed, and Tollefsbol 2010). However, EGCG and pEGCG decreased the level of 
acetyl H3, acetyl- H3K9, and acetyl-H4 to the hTERT promoter in MCF-7 and MDA-MB-
231 cells (Meeran et al. 2011). Genistein inactivated histone trimethyl- H3K9 followed by 
transcriptional repression of hTERT in human breast cancer cells (Li et al. 2009). Long-
term genistein treatment (40-60 days) inhibited the growth of MCF-7 cells and markedly 
reduced the basal expression of acetylated histone 3 (H3) (Jawaid et al. 2010). S-
Allylmercaptocysteine, a metabolite of diallyl disulfide, which is found in garlic and other 
Allium species, has been shown to induce histone acetylation in T47D human breast 
cancer cells (Lea et al. 2002). Resveratrol, a phytoalexin from grape, inhibited the 
growth of BRCA 1 mutant tumor cells by upregulating SIRT1 (the mammalian 
homologue of yeast sir2 belongs to type III HDAC) (Wang et al. 2008). Treatment of 
breast cancer cells with resveratrol induces SIRT1 (a member of the sirtuin protein 
family of NAD+-dependent deacetylase) deacetylase activity, which promotes SIRT1 
association with p300 (an HAT) and down-regulates p300 transferase activity that 
impairs the β-catenin and NFkB-p65 signaling cascades in MCF-7cells (Bourguignon, 
Xia, and Wong 2009). Also, twelve dietary polyphenols evaluated in MCF-7 cells for 
DNA methylation and gene activation analysis by Paluszczak et al. were unable to alter 








2. micro RNA 
 
The most recently emerged participant in the epigenetic field is a family of small 
regulatory RNAs called microRNAs (miRNA), which are small noncoding RNAs ranging 
in size from 19 to 24 nucleotides that inhibit protein expression of target genes (Lewis, 
Burge, and Bartel 2005). These RNAs regulate the expression of target genes by 
sequence specific binding to the 3’-untranslated region (3’UTR) of target mRNAs, 
resulting in either mRNA degradation or inhibition of mRNA translation (He and Hannon 
2004). miRNA can directly or indirectly regulate cancer progression either by acting as 
the tumor suppressor or by altering epigenetic modifying enzymes (Meeran, Ahmed, 
and Tollefsbol 2010). Extensive analyses of genomic sequences of miRNA genes have 
shown that approximately half of them are associated with CpG islands (Weber et al. 
2007, Lehmann et al. 2008). Current bioinformatics tools predict that each miRNA 
recognizes an average of 100-200 different mRNA targets (Lewis, Burge, and Bartel 
2005). Epigenetic silencing of miRNA may be a reflection of tissue specificity. Up 
regulation of miR-205 is seen in lung, bladder, and pancreatic cancers; however, down-
regulation is seen in prostate, breast, and esophageal squamous cell carcinoma (Melo 
and Esteller 2011). Most importantly, expression patterns of miRNAs were correlated 
with tumor stage, proliferation index, estrogen and progesterone receptor expression, 
and vascular invasion (Iorio et al. 2005). Therefore, miRNAs can be used as a 





In breast cancer, epigenetic silencing of several miRNAs is a frequent and early 
event (Veeck and Esteller 2010, Lehmann et al. 2008, Chuang and Jones 2007).  Many 
of the miRNAs including miR-126, miR- 9-1, miR-10b, miR- 125b,miR-145, miR-21, and 
miR-155 are reported to be deregulated in breast cancer (Iorio et al. 2005, Lehmann et 
al. 2008, Si et al. 2007). The differentiation program of epithelial to mesenchymal 
transition (EMT) involves changes in a number of miRNAs. Some of these miRNAs 
have been shown to control cellular plasticity through the suppression of genes involved 
in defining the epithelial and mesenchymal cell states (Zeisberg and Neilson 2009). 
 
Impact of bioactive dietary components on miRNA 
 
Although miRNAs are sensitive to chemical compounds, including the DNA-
demethylating agent 5-AZA, studies with bioactive dietary components and their role in 
miRNA expression and functions in breast cancer are very scarce. One study showed 
that expression of miR-15a and miR-16 was upregulated in curcumin-treated MCF-7 
cells and that upregulation can reduce the expression of Bcl-2 (Yang et al. 2010). In 
other breast cancer cell lines such as SKBR-3 and Bcap-37, curcumin was also able to 










3. DNA Methylation, DNA Methyltransferases and Ten Eleven Translocation family 
of enyzymes  
 
      In mammals, DNA methylation is the most widely studied epigenetic modification 
which results in the addition of a methyl group to the carbon-5 (C5) position in the 
pyrimidine ring of cytosine located in the context of cytosine-phosphate-guanine (CpG) 
dinucleotide of the genomic DNA (Dworkin, Huang, and Toland 2009b). The reaction is 
catalyzed by the enzyme DNA methyltransferase (DNMT) with S-adenosyl-methionine 
(SAM) as the methyl donor (Suzuki and Miyata 2006) (Figure 2). 
 
Figure 2: Schematic illustration of the enzymatic DNA methylation catalyzed by DNMTs 
using SAM as the methyl donor. After the donation of the methyl group (CH3) SAM is 
converted to SAH. SAM= S-adenosyl-L-methionine, SAH= S-adenosyl-homocysteine. 




The number of genes that has been identified to be aberrantly methylated in 
breast cancer is rapidly growing. Studies indicate that in breast cancer, epigenetic 
alterations such as promoter hypermethylation and gene silencing occur in many genes 
participating in apoptosis (HOXA5, RASSF1A, TWIST1), DNA repair (BRCA1), 
metabolic events (GSTP1), tissue invasion, and metastatic processes (CDH1, CDH13) 
(Widschwendter and Jones 2002, Fackler et al. 2004, Pathiraja, Stearns, and 
Oesterreich 2010, Yan et al. 2001). These genes are not only hypermethylated in tumor 
cells but also showed increased epigenetic silencing in normal epithelium surrounding 
the tumor site, which is similar to cancerization (Ushijima 2007). A recent study 
identified 149 genes that are differentially expressed in ER+ versus ER- cells, 
differentially methylated on one or more promoter-proximal CpG islands, and exhibit an 
inverse correlation between CpG island methylation and mRNA abundance (Sun, 
Asmann, et al. 2011). Moreover, many genes identified in breast cancer tissues which 
have hypermethylated CpG islands are located near the consensus sequences of the 
transcription factor binding sites(Radpour R et al. 2009) indicates further that in breast 
cancer the gene expression is also regulated by epigenetic mechanisms. 
In mammals, so far five members of the DNMT protein family have been 
discovered (DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L) of which only three 
were shown to possess catalytic methyltransferase activity (DNMT1, DNMT3A, and 
DNMT3B) (Meeran, Ahmed, and Tollefsbol 2010, Lo and Sukumar 2008, Veeck and 
Esteller 2010). The mammalian DNMTs consist of two parts: the catalytic C-terminal 
domain, which is highly conserved among prokaryotes and eukaryotes, consists of 500 
amino acids, and involved in cofactor binding and catalysis; and the regulatory N-
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terminal part consisting of 621 amino acids, required for discrimination between hemi 
methylated and unmethylated DNA and not essential for enzyme activities. The most 
abundant DNMT is DNMT1, which is a maintenance methyltransferase, positioned at 
the replication fork and maintains the methylation pattern during DNA replication. 
Human DNMT1 is located on chromosome 19p13.2 and consists of 1616 amino acids. 
The DNMT2 is the smallest among the DNMTs (391 amino acids), comprises mainly the 
C-terminal domain, and has no regulatory N-terminal domain. This enzyme participates 
in the recognition of DNA damage, DNA recombination, and mutation repair (Okano et 
al. 1999). Moreover, it was also shown to methylate tRNAAsp (Rai et al. 2007, Goll et al. 
2006) which suggested that the substrate specificity of DNMT2 might be different from 
that of other DNMTs. DNMT3A and DNMT3B are de novo methyltransferases 
upregulated in aging cells and have a C-terminal catalytic domain similar to that in 
DNMT1. The amino acid identity between DNMT3A and DNMT3L is very high, but the 
latter (DNMT3L) lacks any catalytic activity due to the absence of conserved catalytic 
residues. However, DNMT3L is required for the catalytic activity of both DNMT3A and 
DNMT3B. In breast cancer, DNMT3B mRNA was found to be overexpressed (Roll et al. 
2008, Girault et al. 2003). The structure of all DNMTs is now available, but the 
information on DNMT1 is very limited (Medina-Franco et al. 2011). In breast cancer 
patients, the mean level of DNMT1, DNMT3A, and DNMT3B overexpression ranged 






The mechanisms by which DNMT methylates cytosine C5 has been studied 
extensively (Suzuki and Miyata 2006, Medina-Franco et al. 2011, Chen et al. 1991, 
O'Gara et al. 1996). Briefly, DNMT forms a complex with DNA, and the cytosine which 
will be methylated flips out of the DNA double helix. The thiol of the cysteine residue in 
the active sites of the DNMTs acts as a nucleophile that attacks the 6-position of the 
target cytosine to generate a covalent DNA-protein intermediate. The intermediate then 
accepts a methyl group of the methyl-donating cofactor SAM to form the 5-methyl 
covalent adduct and S-adenosyl-Lhomocysteine (SAH). After methyl transfer, the proton 
at the 5 position is attracted by a basic residue in the active site of the enzyme, which is 
removed from the 6-position by β-elimination to generate the methylated cytosine and 
free enzyme. The 5-methylated cytosine base then flips back into its original position 
within the DNA (Medina-Franco et al. 2011, Suzuki and Miyata 2006). DNMTs can also 
silence genes by other mechanisms. The formation of a repressive transcription 
complex by histone deacetylases (HDACs) and the methyl-CpG binding domain (MBD) 
family of proteins at the promoter regions does not require promoter methylation 
(Lustberg and Ramaswamy 2009, Mistry et al. 2003). Moreover, DNMT1 through its N-
terminus binds to HDAC2 and a DNMT1-associated protein called DMAP1 to form a 
complex at the replication fork (Rountree, Bachman, and Baylin 2000). This complex 
converts acetylated histones to the deacetylated inactive form and highlights the 
interplay between methylation and acetylation processes in epigenetic regulation 
(Lustberg and Ramaswamy 2009). DNA methylation of the promoter region of a gene 
has been shown to be an important factor in its ability to bind different transcription 
factors (Campanero, Armstrong, and Flemington 2000, Perini et al. 2005). CpG 
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dinucleotide rich regions located in the 5’-end region of the genes are called CpG 
islands (Pavlopoulou and Kossida 2010). In humans, approximately 60% of the genes 
have CpG islands (Veeck and Esteller 2010).  Methylation of CpG islands is the most 
commonly studied epigenetic change in human cancers (Stearns, Zhou, and Davidson 
2007).  Most CpG islands are unmethylated in noncancerous cells, which promote 
active gene transcription. In cancer cells, CpG islands become hypermethylated, 
leading to the inactivation of tumor suppressor genes. For example, wellknown tumor 
suppressor genes like p16INK4a, APC, and BRCA1 genes are silenced in breast tumors 
due to DNA hypermethylation (Silva et al. 2003, Jin et al. 2001, Birgisdottir et al. 2006). 
However, some genes are activated during carcinogenesis due to hypomethylation. In 
breast cancer, the overexpression of the γ synuclein gene (SNCG) occurs due to SNCG 
promoter hypomethylation (Gupta et al. 2003). 
In addition, recent studies reveal that 5-mC can be converted to 5-
hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), 
respectively by the TET (Ten Eleven Translocation) family of enzymes (Chen et al. 2013, 
Tan and Shi 2012, Hashimoto et al. 2012, He et al. 2011, Ito et al. 2011).  The key 
requirement for the oxidation of 5-mC and 5-hmC is the presence of Fe 2+ and 2-
oxoglutarate. The activation of TET enzymes takes place by electron transfer from the 
iron cofactor. Moreover, 5-hmC, 5-fC, and 5-caC have been proposed as a potential 
intermediates molecules in active DNA demethylation. 5- caC can be recognized and 
cleaved by Thymine- DNA- glycosylase that restore unmethylated cytosine (Dhalluin et 
al. 1999, Eliseeva et al. 2007, Iorio et al. 2005, Lehmann et al. 2008). Alternatively, 
because 5-hmC is more sensitive than 5-mC to deamination (via activation-induced 
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deaminase (AID), in turn it can be converted to cytosine following base-excision repair 
(BER) pathway-mediated demethylation. It remains unknown whether there are 
decarboxylases or deformylases that can remove the modification directly(Chen et al. 
2013, Tan and Shi 2012, Hashimoto et al. 2012, He et al. 2011, Ito et al. 2011 ) so, the 
gene expression can be reactivated (Figure 3). 




Figure 3: Involvement of TET family proteins in the regulation of DNA methylation and 
demethylation. TET family proteins (TET1/2/3) catalyze 5-mC oxidation to 5-hmC. TET 
family proteins can also convert 5-mC or 5-hmC further into 5-fC and 5-caC, and the 
latter may be recognized and excised by thymine DNA glycosylase (TDG) to generate 
cytosine and thereby complete demethylation. Alternatively, because 5-hmC is more 
sensitive than 5-mC to deamination (via AID) which in turn can be converted to cytosine 
following base-excision repair (BER) pathway-mediated demethylation. It remains 
unknown whether there are decarboxylases or deformylases that can remove the 





Impact of bioactive dietary components on DNA methylation 
 
 
There are many bioactive dietary compounds that can modulate methylation  
pattern of genes in breast cancer (Li and Tollefsbol 2010, Meeran, Ahmed, and 
Tollefsbol 2010).  Apigenin in Parsley (Petroselinum), curcumin (1,7-bis (4-hydroxy- 3-
methoxyphenyl)-1,6-heptadiene-3,5-dione) in turmeric (Curcuma longa), EGCG in green 
tea (Camellia sinensis), genistein in soybean (Glycine max), resveratrol (3,40,5-
trihydroxy-trans- stilbene) in red grapes (Vitis vinifera), sulforaphane (SFN) in 
cruciferous vegetables (Brassicacaae), and the caffeic acid and chlorogenic acid as 
coffee polyphenols are reported to inhibit DNMT enzyme activity in various 
cancer/breast cancer models (Meeran, Ahmed, and Tollefsbol 2010, Lee and Zhu 2006). 
Several dietary components such as baicalein, myricetin, protocatechuic acid, phloretin, 
sinapic acid, resveratrol, rosmarinic acid, ellagic acid, betanin, cyanidin, and galangin 
have been studied for potential effects on the activity and expression of DNMTs in 
human breast cancer MCF-7 cell lines (Paluszczak, Krajka-Kuzniak, and Baer-
Dubowska 2010). Among these compounds, betanin was found to be the weakest, and 
rosmarinic and ellagic acids were the strongest inhibitor of DNMT enzymes. But the 
methylation or the expression of RASSF1A, GSTP1, or HIN1 genes in MCF-7 cells 
remained unaltered by these dietary polyphenols. However, decitabine partially 
demethylated and reactivated these genes in MCF-7 breast cancer cells (Paluszczak, 
Krajka-Kuzniak, and Baer-Dubowska 2010). EGCG can also reduce DNMT enzyme 
activities indirectly by reducing S-adenosyl-L-methionine (SAM) and increasing S-
adenosyl homocysteine (SAH) and homocysteine levels (Lee, Shim, and Zhu 2005). In 
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MCF-7 and MDA-MB-231 breast cancer cell lines, EGCG inhibited DNMT and partially 
demethylated retinoic acid receptor β2 (RARβ2), which exists in a hypermethylated 
state in these cells (Lee, Shim, and Zhu 2005).  A novel pro-drug of EGCG (pEGCG) 
and SFN significantly inhibited DNMT activities in MCF-7 and MDA-MB-231 cells and 
down-regulated hTERT expression (Meeran, Ahmed, and Tollefsbol 2010, Meeran et al. 
2011). DNMT1, DNMT3A, and DNMT3B proteins were downregulated in both MCF-10 
AT benign cells and MCF-7 breast cancer cells by genistein (Li et al. 2009). Further, 
genistein and lycopene (a carotenoid derived from tomato) partially demethylated the 
GSTP1 but not RARβ2 gene in MDA-MB-468 (ER-) human breast cancer cells (King-
Batoon, Leszczynska, and Klein 2008). However, an In vivo study indicated that 
genistein hypermethylated RARβ2 and CCND2 genes in the intraductal tissue of 
premenopausal women (Qin et al. 2009).  Resveratrol has been shown to have weaker 
DNMT inhibitory activity than other dietary components such as EGCG (Meeran, Ahmed, 
and Tollefsbol 2010). It was able to inhibit DNMT1 enzyme activity in ERα expressing 
MCF-7 cells significantly but not in MDA-MB-231 cells. Moreover, the promoter 
methylation pattern on the RARβ2 gene remained unaltered by resveratrol in both cell 
lines (MCF-7 and MDA-MB-231) (Stefanska et al. 2010).  Furthermore, in a study with 
MCF-7 cells, it was demonstrated that resveratrol is able to prevent epigenetic silencing 
of the BRCA1 gene induced by the aromatic hydrocarbon receptor (AHR) (Papoutsis et 
al. 2010). Two common coffee polyphenols, caffeic acid and chlorogenic acid, partially 
inhibited the methylation of the RARβ promoter in MCF-7 and MDA-MB-468 cells (Lee 
and Zhu 2006). The mechanisms of inhibition of the DNMT enzyme activity by these 
bioactive compounds in breast cancer models was also studied by many investigators. 
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The classical synthetic inhibitor 5-AZA, a cytidine analogue, inhibits the DNMT enzyme 
by forming irreversible covalent bonds with DNMT1 and incorporating itself into the 
replicating DNA, which induces the degradation of DNMT1(Miyamoto and Ushijima 
2005, Schaefer et al. 2009).  The non-nucleoside DNA methylation inhibitors (such as 
procainamide) demethylate DNA by binding to GC-rich DNA sequences (Zacharias and 
Koopman 1990). Bioactive natural products such as quercetin, fisetin, and myricetin 
which have catechol structures are readily methylated by SAM in the presence of 
catechol O-methyltransferase (COMT), resulting in the conversion of SAM to SAH (Lee 
and Zhu 2006, Lee, Shim, and Zhu 2005). By using molecular modeling techniques, it 
was demonstrated that EGCG, a nonnucleoside analogue and a competitive inhibitor of 
DNMT1, exerts its inhibitory effect by blocking the entry of the key nucleotide cytosine 
into its active site by hydrogen bonds and Mg2+ can enhance the reaction (Fang et al. 
2003). Other tea polyphenols, such as (-)-epicatechin, (-)-epicatechin-3-gallate, (-)-
epigallocatechin have also been implicated in DNA methylation inhibition; however, they 
are not as potent as EGCG (Li and Tollefsbol 2010). The coffee polyphenols, caffeic 
acid and chlorogenic acid, inhibit DNA methylation indirectly (noncompetitive) by 
forming SAH, as a consequence of COMT-mediated O-methylation (Lee, Shim, and Zhu 
2005). Genistein showed both competitive and noncompetitive inhibition of DNMT 
activity (Fang et al. 2005). Molecular docking analysis of the interaction between 
curcumin and DNMT1 suggested that curcumin covalently blocks the catalytic thiolate of 
C1226 of DNMT1 to exert its inhibitory effect (Liu et al. 2009, Fu and Kurzrock 2010). 
The inhibition by curcumin seems to be comparatively lower than that of other bioactive 
dietary components such as EGCG and genistein (Fu and Kurzrock 2010, Liu et al. 
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2009, Fang, Chen, and Yang 2007). 
 
Tumor Metastasis  
One of the classical hallmarks of cancer is the ability for tumor cells to invade and 
metastasize (Hanahan and Weinberg 2011). The metastatic properties of tumor cells 
were extensively investigated in the late 1970s and early 1980 by means of 
experimental metastasis assays (Weigelt, Peterse, and van 't Veer 2005). For example, 
studying the metastatic behavior of cultured B16 melanoma cells that were injected 
intravenously into mice showed that cells derived from outgrowths of these cells have a 
higher metastatic potential than those derived from original cell line (Fidler 1973).  Also, 
In vitro clones from the parent B16 culture varied greatly in their ability to produce lung 
metastases after intravenous injection into mice (Fidler and Kripke 1977). These 
observations led to a metastasis model. The metastases represent the end products of 
a multi step cell- biological process termed the invasion-metastasis cascade (Valastyan 
and Weinberg 2011) whereby epithelial cells in primary tumors, (1) invade locally 
through surrounding extracellular matrix (ECM) and stromal cell layers, (2) intravasate 
into the lumina of blood vessels, (3) survive the rigors of transport through the 
vasculature, (4) arrest at distant organ sites, (5) extravasate into the parenchyma of 
distant tissues, (6) initially survive in these foreign microenvironments in order to form 
micrometastases, and (7) reinitiate their proliferative programs at the metastatic sites, 
thereby generating macroscopic, clinically detectable neoplastic growths or metastatic 
colonization (Valastyan and Weinberg 2011, Friedl and Wolf 2003). Each of metastatic 
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stages is driven by the acquisition of genetic and/or epigenetic alterations within tumor 
cells and the co-option of nonneoplastic stromal cells (Valastyan and Weinberg 2011). In 
addition to remodeling the microenvironment to facilitate metastasis, cancer cells also 
turn on embryonic morphogenesis regulators to undergo the epithelial-to- mesenchymal 
transition (EMT) and turn off differentiation programs, allowing cancer cells to gain 
motility, modify cell adhesion and acquire stem-like properties such as  self-renew and 
are able to generate the diverse tumor cells (Chou et al. 2013). In contrast to EMT, 
differentiation is associated with less aggressive tumors and better prognosis. The 
emergence of metastases is responsible for over 90% of cancer patient deaths 
(Abdelkarim et al. 2011, Gupta and Massague 2006). Patients with basal-type tumors 
lacking estrogen receptor (ER-), progesterone receptor (PR-) and ErbB2- referred to as 
basal triple- negative breast cancer (BTNBC) that have a worse prognosis compare to 
patients with more differentiated, less metastatic tumor expressing markers of the 
luminal lineage including the transcription factors GATA3 and ER (Neve et al. 2006, 
Perou et al. 2000, Sorlie et al. 2003). 
 
GATA binding protein 3 (GATA3) 
GATA-binding protein 3 (GATA3) is a member of the GATA family of zinc finger 
transcription factors (GATA1–GATA6)  that binds with high affinity to the consensus DNA 
site (T/A-GATA-A/G) (Amatori et al. 2010, Ordway et al. 2007).  GATA3 plays an 
essential role in T cell development and the specification of the Th2 subset of T cells. 
Additionally, GATA3 performs critical functions outside of the hematopoietic system, 
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including a role in the development of epithelial structures of skin, inner ear, central 
nervous system, kidney, and importantly for the proposed studies, the mammary gland 
(Amatori et al. 2010, Kouros-Mehr et al. 2008, Kouros-Mehr et al. 2006, Ordway et al. 
2007, Yan et al. 2010, Yoon et al. 2010). GATA3 is essential in breast glandular cell 
development. In particular, GATA3 is necessary for embryonic mammary development 
and is actively involved in maintaining the differentiated state of luminal epithelial cells 
of the mammary gland in adults (Kouros-Mehr et al. 2008, Kouros-Mehr et al. 2006, Yan 
et al. 2010). In breast cancer, GATA3 has emerged as a strong and independent 
predictor of tumor differentiation and clinical outcome (Amatori et al. 2010, Kouros-Mehr 
et al. 2008, Kouros-Mehr et al. 2006, Ordway et al. 2007, Yan et al. 2010, Yoon et al. 
2010). The low expression of GATA3 in breast cancer correlated with a poorer outcome 
related to high tumor grade (poorly differentiated or undifferentiated), larger tumor size, 
and short disease- free survival (Amatori et al. 2010, Kouros-Mehr et al. 2008, Kouros-
Mehr et al. 2006, Ordway et al. 2007, Yan et al. 2010, Yoon et al. 2010). The expression 
of GATA3 also positively related to elevated E-cadherin, but decreased vimentin, N-
cadherin and MMP-9, which suggests that GATA3 may drive the invasive breast cancer 
cells to undergo the reversal of epithelial-mesenchymal transition, which can lead to the 
inhibition of metastasis. Importantly, increasing GATA3 expression in the low expressing 
MDA-MB-231 breast cancer cells led to cancer cells differentiating and decreased their 
invasive potential in vitro (Chou et al. 2013, Chu et al. 2012, Yan et al. 2010), and 
decreased tumor formation in vivo (Yan et al. 2010). Therefore, GATA3 is an important 




























Figure 4: Proportion of breast cancers defined by expression of the estrogen receptor 
(ER), human epidermal growth factor 2 (Her2) and GATA3, together with prognosis 
(Gaynor et al. 2013). 
 
Efforts to develop drugs for breast cancer treatment have yielded many 
successes. However, breast cancer remains the second leading cause of cancer death 
in American women (Amatori et al. 2010). This high incidence of mortality highlights the 
need for new therapeutics. One new potential source for therapeutics is plants used in 
traditional Chinese medicine (TCM) which have been successfully used for treatment of 
many diseases, including cancer (Medina-Franco et al. 2011, Newman 2008). Studies 
of natural products, such as tea polyphenols, genistein, diadzein, equol, and grape seed 
extracts, indicate that these agents either alone or in combination have the potential to 
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be used as therapeutic agents in breast cancer (Fang et al. 2003, Newman 2008). 
Dioscorea villosa (wild yam) 
Plants belong to the genus Dioscorea is found in the tropical and temperate regions of 
the world comprising more than 600 species. Dioscorea villosa is the North American 
native of this genus and the roots and rhizomes of this species (Dioscorea villosa) are 
known as wild yam. These plants contain steroidal saponins and are widely used as 
botanical dietary supplements. Herbalists have been using wild yam to treat menstrual 
cramps and other problems related to child birth, stomach upset and coughs (Carroll 
2006). Dietary supplements containing wild yam extracts are used by women for 
alleviation of menopausal symptoms and also served as an alternative to hormone 
replacement therapy. The components of wild yam root extract (WYRE) belonging to 
steroidal saponins and sapogenins are found to be noncarcinogenic (2004). To our 
knowledge, fourteen steroidal saponins, two flavan-3-ol glycosides and fourteen 
diarylheptanoids have been reported from wild yam (Ali, Smillie, and Khan 2013, Dong 
et al. 2007, Hayes et al. 2007, Sautour, Miyamoto, and Lacaille-Dubois 2006, Yoon et al. 
2010); among them diosgenin and dioscin exhibit anticancer activity (Jagadeesan et al. 
2012). WYRE was able to reduce cell proliferation, increase the expression of 
progesterone receptor and pS2 mRNA and down regulate ERα protein (Park et al. 
2009). Moreover, diosgenein, (a steroidal saponin and aglycone of dioscin) isolated 
from the rhizomes of wild yam, have the potential to stimulate the growth of mammary 
epithelium of ovariectomized mice (Aradhana, Rao, and Kale 1992) and effectively 
suppress fatty acid synthase expression in HER2-overexpressing breast cancer cells 
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(Chiang et al. 2007). Dioscin, a plant glucoside saponin, was shown to inhibit autophagy 
and enhance apoptosis in a number of human carcinoma cell lines with an IC50 value 
typically in uM concentrations (Hsieh et al. 2012, Liu et al. 2004, Mi et al. 2002, Cai et al. 
2002, Chen et al. 2014, Gao et al. 2011, Wang et al. 2012). For instance, Liu et al, 2004 
showed that dioscin was able to induce cytotoxicity and apoptosis in human myeloblast 
leukemia HL-60 cells (Liu et al. 2004). Sun et al, 2011 demonstrated that dioscin 
reversed effect on multi drug resistants in human hepatoma (HepG2/adriamycin cells) 
(Sun, Zheng, et al. 2011). Gao et al, 2011 showed the G2/M phase arrest and apoptosis 
effect in SGC-7901 (human gastric cancer cells) by dioscin (Gao et al. 2011). Also, 
recently study by Chen et al 2014 showed that dioscin (1, 2 and 4 μM) could 
significantly inhibit the viability of LNCaP cells in a time- and concentration-dependent 
manner and apoptosis was an important mechanism by which dioscin inhibited prostate 
cancer cells (Chen et al. 2014). However, there have been no studies reported 






      
 
 








Figure 6:  Structure of Dioscin (A) and Diosgenin (B) isolated from wild yam (Dioscorea 
villosa) (Ali, Smillie, and Khan 2013). 





CENTRAL HYPOTHESIS AND SPECIFIC AIMS 
 
 
We hypothesized that wild yam has the potential to be used in breast cancer 
therapy and their efficacy in epigenetic regulation need evaluation. Moreover, to our 
knowledge, there have been no studies reported concerning the molecular mechanism 
of tumor invasion/migration reversion by dioscin. Accordingly, we further investigate the 
anti-tumor invasion/migration activity of dioscin.  
 
Specific aim 1 
Evaluate the efficacy of wild yam (Dioscorea villosa) as a potential GATA3 
upregulators in human breast cancer cells. 
  
Specific aim 2 
Establish mechanism(s) of anti cancer activity of wild yam root extract (WYRE) 





CHAPTER 3  
MATERIALS AND METHODS 
3.1 Cell culture  
 
Human breast adenocarcinoma, MCF-7 (ER+) and MDA-MB-231 (ER) cells were 
maintained in phenol red free DMEM-F12 (1:1) medium supplemented with 10% 
dextran charcoal treated fetal bovine serum (Atlanta Biologicals, Atlanta, GA), 50 U/mL 
penicillin and 50 µg/mL streptomycin as Pen-Strep (Life Technology, Grand Island, NY) 
and 2 mM of L-glutamine (Life Technolgy, Grand Island, NY)  at 37 0C in a humidified 
atmosphere of 95% air and 5% CO2. 
 
3.2 Cell viability assay and IC50 determination 
 
MCF-7 and MDA-MB-231 cells in logarithmic growth were seeded at a density of 2x 104 
cells/ well (for 24 h of incubation after adding treatments)   and 7.5x103 cells/ well (for 
72 h of incubation after adding treatments)  in 96 well plates and grown at 37 oC in a 
humidified atmosphere of 95% air and 5% CO2 for 24 h. Stock of WYRE, dioscin and 
diosgenin dissolved in DMSO at concentration of 2 mg/mL and 5-AZA at concentration 
of 1 mM were diluted in serum-free medium supplemented with antibiotics and added to 
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the wells to achieve the desired concentrations in a 250 µl final volume and incubated 
for 72 h. Only dioscin was incubated for 24 h and 72 h.  DMSO (0.01%) was used as 
vehicle control. Cell viability was determined by XTT method(Scudiero et al. 1988). In 
brief, 25 µl of 25 μM N-methyl dibenzopyrazine methyl sulfate-XTT (PMS-XTT) (Sigma-
Aldrich, St. Louis, MO) solution was added to each well and incubated for 4 h at 37 0C. 
The absorbance was measured by a spectrophotometer at 450 nm. Percent cell viability 
was calculated compared to vehicle control.  
 
3.3  RNA extraction 
 
The MCF-7 and MDA-MB-231 cells (500 x 103 cells/ mL) were allowed to attach in the 
25 cm3 culture flasks and cells  were treated with various concentrations of WYRE (10-
50 μg/mL), 5-AZA (250-1000 nM), Dioscin (1.15-5.76 μM) and Diosgenin (2.41-24.14 
μM)  for three days. After removing the medium completely, cells were trypsinized, 
resuspended in the medium and counted. After washing twice with PBS, the cells were 
used for RNA and DNA extraction by Trizol reagent following manufacturer’s instructions 
(Invitrogen, Carlsberg, CA). Briefly, cells were lysed in Trizol reagent by repetitive 
pipetting and incubated for 5 minutes at 15-30 0C then added 200 µL of chloroform per 
1mL of Trizol reagent and caped sample tubes securely and shaked tubes vigorously by 
hand for 15 seconds and incubated them at 15-30 0C for 2-3 minutes. Samples were 
centrifuged at 12,000xg for 20 minutes at 4 0C. Following centrifugation, the mixture 
separated into a lower red, phenol-chloroform phase, and a colorless upper aqueous 
phase. The aqueous phase was transferred to fresh tube and precipitated the RNA by 
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mixing with isopropyl alcohol. Then, samples were incubated at 15-30 0C for 10 minutes 
and centrifuged at 12,000xg for 20 minutes at 4 0C. The supernatant was removed and 
washed RNA pellet twice with 75% alcohol. At the end of the procedure, dry the RNA 
pellet (air- dry) for 10 minutes.  The extracted RNA samples were dissolved in nuclease-
free water. Before cDNA synthesis, RNA samples were treated with RQ1 DNase 
(Promega, Madison, WI) to ensure removal of contaminating genomic DNA. The 
concentration of the RNA was determined by NanoDrop 2000c (Thermo Fisher 
Scientific, Waltham, MA) and stored at -80 0C until analysis.  
 
3.4 DNA extraction 
 
 
The samples fractions remained after RNA fractions separations were utilized for DNA 
extraction. DNA from the interphase and organic phase was precipitated with ethanol 
and mixed samples by inversion. The samples were stored at room temperature for 2-3 
minutes and sedimented by centrifugation at 2,000xg for 5 minutes at 4 0C. Then, the 
samples were removed the phenol ethanol supernatant fraction, and washed the DNA 
pellet twice in a solution containing 0.1M sodium citrate in 10% ethanol. At each wash, 
DNA pellets were stored in the washing solution for 30 minutes at room temperature 
with intermittent shaking and centrifuged at 2,000xg for 5 minutes at 4 0C. Following two 
washes, the DNA pellets were suspended in 75% ethanol for 10- 20 minutes at room 
temperature with periodic mixing and centrifuge at 2,000xg for 5 minutes at 4 0C. Finally, 
air dried the DNA for 5-15 minutes in the open tube and dissolved DNA pellets in 8mM 
NaOH. The concentration of the DNA was determined by NanoDrop 2000c (Thermo 




3. 5 Quantitative real-time PCR (qPCR) 
 
 
Gene-specific mRNA analysis was done by qPCR methods based either on PCR array 
(SA BioScience, Valencia, CA) or by previously standardized methods (Hu, Khan, and 
Dasmahapatra 2008, Livak and Schmittgen 2001, Wu et al. 2010). In brief, extracted 
RNA was reverse transcribed to cDNA by iScript reverse transcriptase following the 
manufacturer’s instructions (Bio-Rad, Hercules, CA). Two μL of cDNA in a final reaction 
volume of 20 μL was amplified with gene-specific or internal controls (RPL-19) primers 
either in PCR array plates (DNMT1, DNMT3A, DNMT3B, GATA3, ZFPM2, CDH1, 
MMP9, and VIM) or in PCR tubes (TET1, TET2 and TET3). The primers (DNMT1, 
DNMT3A, DNMT3B, GATA3, ZFPM2, CDH1, MMP9, VIM and RPL-19) used in the PCR 
array were designed and added to the plates by the manufacturer (SA BioScience, 
Valencia, CA), however, the primers used for TET enzyme mRNAs (TET1: GenBank 
accession: NM_030625, sense: 5’-CCATATTATACACACCTTGGG-3’, anti-sense: 5’-CT 
CCATGAACAGCCAAAAGAG-3’; TET2: GenBank accession: NM_017628, Sense:5’-
GGGCAGCCTTGTGGATGGCCC-3',  Antisense:5'-GG AGCCCAGAGAGAGAAGGTT-3’; 
TET3: GenBank accession: NM_144993, sense 5’-ATGGACTCAGGGCCAGTGTAC-3’, 
antisense: 5’-GTTCCCAGCCTCACGACTCA TC-3’) and ACTB (GenBank accession: 
BC002409, sense:5’-AGCGAGCATCCCCCAAAGTT-3’, antisense: 5’-
GGGCACGAAGGCTCATCATT-3’) were purchased from Integrated DNA Technologies 
(IDT, Coralville, IA) and the nucleotide sequences of the amplified PCR products were 
analyzed by a commercial source (Retrogen, San Diego, CA) and verified with 
GenBank data base. The reaction conditions included an initial denaturation at 95 0C for 
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3 min, one cycle, followed by 40 cycles of denaturation at 94 0C for 30 sec, annealing 
60 sec at 60 0C, and extension 120 sec at 72 0C, fluorescence data collection for 1 sec. 
After the end of each cycle the samples were incubated again for 1 sec at 78 0C and a 
second set of fluorescence data collection was made to prevent error due to formation 
of primer dimmers, if any. A final extension of one cycle at 72 0C for 10 min was made. 
The melting curve was constructed by plotting fluorescence data (1 sec) against 
temperature (65 0C to 95 0C with an interval of 0.2 0C and a holding time of 0.5 sec). 
Each reaction was performed in duplicate. The cycle threshold or C (t) line was set at the 
point where the signals surpass background noise and began to increase. This 
threshold was applied to all wells for consistent analysis. For each sample, the 
threshold cycle for internal standard (RPL19 or ACTB) amplification (Ct, RPL 19; Ct, 
ACTB) was subtracted from the threshold cycle of the corresponding genes mRNA 
amplification such as GATA3 was Ct, GATA3 to yield ΔCt. For each treatment group, the 
mean ΔCt of control samples was subtracted from individual samples to yield individual 
ΔΔCt. Fold induction relative to control samples was calculated by  2-ΔΔCt.  
To determine GATA3 mRNA copy, the internal standards were prepared in the 
laboratory by amplifying cDNA with GATA3 gene-specific (GenBank Accession 
NM_002051) sense (5'-CTCATTAAGCCCAAGCGAAGG-3') and antisense (5'-
TTTTTCGGTTTCTGGTCTGG-3') primers (IDT, Coralvolle, IA) in a 20 μL final volume 
containing buffer and other necessary ingredients including Taq DNA polymerase and 
Mg2+ (Qiagen, Valencia, CA). The reaction conditions were: 94 0C 2 min 1 cycle, 
followed by 40 cycles of denaturation 94 0C, 0.5 min, annealing 60 0 C, 1 min, extension 
72 0 C, 2 min, and final extension 72 0C for 7 min, one cycle. The amplified PCR product 
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was separated electrophoretically in 1% agarose gel containing 0.01% ethidium 
bromide, eluted, and quantified in NanoDrop 2000c (Thermo Fisher Scientific, Waltham, 
MA). The standards were (206 bp) aliquoted into separate tubes and stored at -80 0C 
until use. During qPCR (DNA Engine Opticon 2, Bio-Rad), the standards were diluted to 
require concentration (copy numbers) with nuclease free water and run in parallel with 
the samples for amplification. The quantification cycle or Cq was set at the point 
manually with the best R2 value ranged from 0.80-0.99 for standard curves. The copy 
number of GATA3 mRNA in each sample tube was determined by using MJ Opticon 
Monitor Analysis software, version 3.1 (Bio-Rad, Hercules, CA). The GATA3 mRNA 
copy was expressed as mRNA copy /ng of total RNA.  
 
3.6 Global DNA methylation and global DNA hydroxymethylation analysis 
 
 
Global DNA methylation as 5-methylcytosine (5-mC) was determined by competitive 
ELISA (Cell Biolabs, San Diego, CA) using anti-5'-methyl-2'-deoxycytidine (anti-
5MedCyd) monoclonal antibody by following the instructions provided by the 
manufacturer. In brief, isolated genomic DNA was denatured at 95 0C for 5 min and then 
rapidly chilled on ice. The samples (denatured DNA) were incubated at 37 0C for 2h with 
P1 nuclease (Sigma-Aldrich, St. Louis, MO) in 20 mM sodium acetate buffer, pH 5.2. 
Samples were further treated with alkaline phosphatase (NEB, Ipswich, MA) for 1 h at 
37 0C in 100 mM Tris (pH 7.5). After centrifugation at 6000*g for 5 min the supernatant 
was used for 5MedCyd ELISA assay. The color was developed by a secondary antibody 
conjugated with HRP. The reaction was stopped after 1h by adding stop solution and the 
plate was read at Spectra Max M5 (Molecular Devices, Sunnyvale, CA) at 450 nm. The 
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data were calculated against a standard curve made from 5MedCyd run in parallel with 
genomic DNA.   
Hydroxymethylated DNA (5-hmC) was also determined by an ELISA-based protocol 
(Cell Biolabs) with anti-5hmC antibody. In brief, the isolated DNA was diluted in PBS (2 
μg/mL) and added to the wells of the DNA-High-Binding plate provided by the 
manufacturer for adsorption. The DNA was adsorbed in wells overnight at 4 0C followed 
by washing twice with PBS. After removal of excess PBS, 150 μL of assay diluents was 
added to each well and incubated at room temperature for 1h with orbital shaking. The 
wells were washed three times with 250 μL of wash buffer (1X) followed by addition of 
150 μL of blocking reagent to each well. The plate was left at room temperature for 60 
min, washed 3 times with wash buffer and 150 μL of HRP-conjugated secondary 
antibody was added to each well. The wells were washed three times with wash buffer 
followed by the addition of 100 μL of substrate to each well. After 30 min incubation at 
room temperature 100 μL of stop solution were added to each well and read 
immediately at 450 nm in a Spectra Max (M5).   
 
3.7 Gene-specific methylation analysis of specific locations of GATA3 promoter  
 
 
We have used genomic DNA for methylation analysis of a specific locus of GATA3 
promoter using restriction endonuclease-sensitive analysis technique (Iida et al. 2006, 
Oakeley 1999). The nucleotide information of GATA3 gene promoter were obtained from 
Ensembl (www.ensembl.org) (GATA binding protein 3: Gene ID ENSG 00000107485) 
considering 5000 bp upstream of ATG and the first exon which gave a total 5175 
nucleotides for GATA3 promoter sequence. By using methyl primer express version 1.0 
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software (Life Technology) we have detected three CpG islands in the promoter region 
of GATA3 gene (defined as greater than 100 bp, greater than 50% GC, and greater than 
60% observed/expected ratio). By designing gene-specific primers for GATA3 (sense: 
5'-CTACCGGCTGGCTCCATTACC-3' and antisense: 5'-GTTGCTGTCTAACATTCA 
CCG-3',) and using genomic DNA as a template, we were able to amplify a 580 bp 
fragment for GATA3 (spanned from -1994 to -2573 nucleotide, ATG =+1) in PCR 
conditions, 94 0C for 2 min, one cycle followed by denaturation at 94 0C, 30 sec, 
annealing 62 0C, 1 min and extension 72 0C, 2 min, 40 cycle, final extension 7 min at 72 
0C. The nucleotide sequences were verified with the sequences reported in the data 
base which showed 100% identity. Further analyses of the nucleotide sequences of the 
amplified product of GATA3 (580 bp) consists thirty-two 5'-CG-3' sites and six 5'-CCGG-
3' sites. Once we confirmed about the amplified product, the extracted genomic DNA (1 
μg) was digested separately with MspI, (40 units) and HpaII (20 units) restriction 
endonuclease (RE) enzymes (NEB, Ipswich, MA) overnight at 37 0C in a 20 μL reaction 
volume and inactivated for 20 min at 65 0C. Samples with equivalent amount of DNA in 
identical conditions with no RE enzymes were used as uncut controls. Two μL of each of 
RE digested DNA and parallel uncut controls were used for quantification by qPCR 
using GATA3 primers as target and ACTB primers (sense: 5'-
AGCGAGCATCCCCCAAAGTT-3' and antisense: 5'-GGGCACGAAGGCTCATCATT-3'; 
IDT, Coralville, IA) as internal controls. The genomic region annealed and amplified by 
ACTB primers has no 5'-CCGG-3' sites, therefore, cannot be recognized by MspI or 
HpaII RE and the amplified product should be intact (285 bp). The qPCR conditions 
were identical as mentioned above. Each reaction was performed in duplicate. During 
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analysis, the C(t) line was set at the point where the signals surpass background noise 
and began to increase. This threshold was applied to all wells for consistent analysis of 
target (GATA3) and ACTB amplification. For each sample, the threshold cycle for 
internal standard (ACTB) amplification (Ct, ACTB) was subtracted from the threshold 
cycle of the corresponding GATA3 amplification (Ct, GATA3)) to yield ΔCt. For each 
treatment group, the ΔCt data of uncut control samples was subtracted from individual 
samples including MspI and HpaII digested samples to yield individual ΔΔCt. Amplified 
DNA products of GATA3 relative to uncut control samples was calculated by 2-ΔΔCt. 
 
 




MCF-7 or MDA-MB-231 cells were plated in 6-well plate in a concentration of 3x105  
cells in 4 mL of growth medium.  After 24 h dioscin at 1.15, 2.30, 5.76 μM and DMSO 
(0.01%) was used as vehicle control were added and incubated at 37 0C in a humidified 
atmosphere of 95% air and 5% CO2 for 72h. Cells were rinsed twice with ice-cold PBS 
and collected by scraping and then extracted in a lysis buffer ( pH7.4) for 1 h at 4 0C 
with occasional rocking. The lysates were passed through a 21- gauge needle (on ice) 
to shear the DNA and centrifuged at 10,000xg for 20 mins at 4 0C.  Supernatants were 
collected for protein analysis. Supernatants were mixed with equal volume of 2X SDS 
sample buffer, boiled for 5 mins and then separated through a 10% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (Biorad, Hercules, CA).  After electrophoresis, 
proteins were transferred to polyvinylidenefluoride membrane (Biorad, Hercules, CA) 
and blocked with 5% nonfat dry milk (Santa Cruz Biotechnology, Dallas, TX) for 1h at 
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room temperature. The membrane was immunoblotted with goat anti-GATA3 polyclonal 
antibody (1:100) (Santa Cruz Biotechnology, Dallas, TX) at 4 0C over night and 
membrane was washed 3 times with washing buffer (Life Technology, Grand Island, NY) 
and incubated in horseradish peroxidase-labeled donkey anti-goat antisera (1:2000) 
(Santa Cruz Biotechnology, Dallas, TX) for 1 h at room temperature. Western blotting 
luminol reagent (Santa Cruz Biotechnology, Dallas, TX) was used for detection of 
GATA3 protein. Also, membrane was incubated with rabbit anti β-actin (1:2400) at 4 0C 
over night, washed 3 times with washing buffer (Life Technology, Grand Island, NY) and 
was incubated with biotin–conjugated goat anti-rabbit IgG for 1h at room temperature. 
β-actin proteins were visualized with streptavidin-conjugated HRP.  
 




MDA-MB-231 and MCF-7 cells were plated in chamber slide (MERCK Millipore, 
Billenrica, MA) at concentration 2.5x104  cells/well in 500 μL of growth medium.  After 24 
h dioscin at 5.76 μM and DMSO 0.01% (vehicle control) were added and incubated at 
37 0C in a humidified atmosphere of 95% air and 5% CO2 for 72h. Cells were fixed with 
4% formaldehyde and blocked with PBS containing 5% BSA for 1h followed by 
incubation with rabbit anti-GATA3 polyclonal antibody (1:50) (Santa Cruz Biotechnology, 
Dallas, TX) overnight at 4 0C. Slides were washed 3 times with washing buffer (Life 
Technology, Grand Island, NY). Then a goat anti-rabbit IgG fluorescein conjugated 
secondary antibody (1:200) (Thermoscientific, Pittsburgh, PA) was added and incubated 
for 1 h. Then slides were washed 3 times with washing buffer (Life Technology, Grand 
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Island, NY) and counterstained with DAPI (Life Technology, Grand Island, NY). 
Florescence was examined by confocal microscope LSM 510.  
 
3.10  Wound healing assay 
 
 
MDA-MB-231 cells were seeded into 24-well tissue culture plate at a density of 3x105 
cells/well. After 24 hours of growth, cells reach ~70-80% confluence as a monolayer. 
Then, the cell monolayers were gently and slowly scratched on with a micropipette tip 
across the center of the well. After scratching, the wells were washed twice with medium 
and replenished the wells with fresh medium that contained DMSO as control and 
various concentrations of dioscin 1.15, 2.30, and 5.76 μM.  Each wells were 
photographed under phase contrast microscope at 4X objectives at 0, 12, 18 and 24 
hours. Pictures were analyzed by using Wimasis Image Analysis by IBIDI®, Verona, WI.  
 
3.11 Cell migration assay  
 
 
Cell migration was determined by using Boyden chambers with an 8 micron 
polyethylene terephthalate (PET) membrane and detect the quantity of cell migration by 
using fluorescein technique by following the instruction provided by manufacturer 
(Trevigen, Gaithersburg, MD). Briefly, twenty-four hours prior to beginning assay, 
starved cells in a serum- free medium to allow expression of free receptors. MDA-MB-
231 and MCF-7 cells preincubated with serum-free medium with DMSO as control and 
various concentration of dioscin at 1.15, 2.30, and 5.76 μM were transferred onto top 
invasion chamber with cell density of 50,000 cells/well. Using access port, added 150 
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μL of medium per well to bottom chambers. The chambers were incubated at 37 0C in a 
humidified atmosphere of 95% air and 5% CO2 for 24h. Then carefully aspirated top and 
bottom chambers and washed with washing buffer. The top chamber was transfered to 
assay chamber plate and added 100 μL of cell dissociation solution/Calcein–AM to 
bottom chamber and incubated at 37 0C in a humidified atmosphere of 95% air and 5% 
CO2 for 1h. Then, remove top chamber, the plates were read at 485nm excitation, 520 
nm emission.  Using standard curve converted Relative Fluorescence Units (RFU) to 
cell numbers and determined cell migrations as percent of controls.  
 
3.12 Cell invasion assay  
 
 
Cell invasion was determined by employing Boyden chambers with an 8 micron 
polyethylene terephthalate (PET) membrane that were coated with Basement 
membrane Extract (BME) and detected the quantity of cell invasion by using fluorescein 
technique by following the instruction provided by manufacturer. (Trevigen, Gaithersburg, 
MD) Briefly, twenty-four hours prior to beginning assay, starved cells in a serum- free 
medium to allow expression of free receptors. Coated membrane of top invasion 
chamber with 0.5X  BME solution and incubated for 4 h at room temperature.  MDA-MB-
231 and MCF-7 cells preincubated with serum-free medium with DMSO as control and 
various concentration of dioscin at 1.15, 2.30, and 5.76 μM were transferred onto top 
invasion chamber with cells density of 50,000 cells/well. Using access port, added 150 
μL of medium per well to bottom chambers. The chambers were incubated at 37 0C in a 
humidified atmosphere of 95% air and 5% CO2 for 24h. Then carefully aspirated top and 
bottom chambers and washed with washing buffer. The top chamber was transfered to 
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assay chamber plate and added 100 μL of cell dissociation solution/Calcein-AM to 
bottom chamber and incubated at 37 0C in a humidified atmosphere of 95% air and 5% 
CO2 for 1h. Then, remove top chamber, the plates were read at 485nm excitation, 520 
nm emission.  Using standard curve converted Relative Fluorescence Units (RFU) to 
cell numbers and determined cell invasion as percent of controls.  
 
3.13  Statistics  
 
 
Statistical significance was assessed using an unpaired t-test or one-way ANOVA 
followed by Tukey’s post-hoc multiple comparison test to evaluate the  differences 
between control and various treatment groups with the use of GraphPad Prism version 
5.0 (GraphPad Software, San Diego, CA). The data were presented as mean  SEM 






1.1 Identification of CpG islands in GATA3 gene promoter.  
Methyl Primer Express V1.0 software (Applied Bioscience) was used for searching CpG 
islands on the nucleotides (5175 nucleotides located upstream of ATG in GATA3 gene) 
using CpG island size 200-2000 bp. C+Gs/ total bases >50% and CpG observed/CpG 
expected <0.6. There are three CpG rich sites in the promoter region of GATA3 and 
CpG island were 2000, 2000, and 988 bp.
 
Table 1. Distribution of CpG islands of GATA3 gene by using Methyl Primer Express 




1.2 Effects of WYRE on GATA3 mRNA expression as copy number 
 
GATA3 mRNA analysis as copy number indicates that MCF-7 cells have comparatively 
higher copy numbers of GATA3 mRNA than MDA-MB-231 cells. WYRE at the doses of 
25-50 μg/mL was able to significantly increase GATA3 mRNA copy numbers  in both cell 
lines when compared with controls (Figure 8).  
GATA3 mRNA Copy







































Figure 7: Constant number of cells (500 x10 3) were cultured in 25 cm3 cell culture 
flasks and cells were treated with WYRE (0-50 µg/mL) for 72 h. After removing the 
medium completely, the cells were trypsinized, resuspended in the medium and counted.  
Total RNA was extracted from cell pellets by Trizol reagent and used for mRNA analysis 
by copy numbers against GATA mRNA standard curve. Each bar is the mean SEM of 
eight observations. Bar head with asterisks (*) indicate that the data are significantly 
different from controls. The GATA3 mRNA expression was found to be enhanced in a 
concentration-dependent manner in both cell lines. GATA3 mRNA expression in MCF-7 
cells was higher (approximately 10 fold) than in MDA-MB-231 cells.   
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1.3  Effects of WYRE and 5-AZA on GATA3 mRNA expression. 
 
GATA3 mRNA expression relative to RPL19 was increased significantly in both MCF-7 
and MDA-MB-231 cells treated with 50 μg/mL WYRE. Lower concentrations of WYRE 
(10-35 μg/mL) were unable to alter GATA3 mRNA content in both cell lines (Figure 8.1). 
Moreover, GATA3 mRNA content relative to RPL19 was increased significantly only in 
MDA-MB-231 cells at 1 μM of 5-AZA. Other 5-AZA concentrations in MDA-MB-231 cells 
were unable to alter GATA3 mRNA expression. Also, MCF-7 cells were irresponsive to 
5-AZA (250-1000 nM) (Figure 8.2). 
 
GATA3 mRNA




































































Figure 8: Constant number of cells (500 x10 3) were cultured in 25 cm3 cell culture 
flasks and cells were treated with WYRE (0-50 µg/mL) and 5-AZA (0-1000 nM) for 72 h. 
After removing the medium completely, the cells were trypsinized, resuspended in the 
medium and counted.  Total RNA was extracted from cell pellets by Trizol reagent and 
used for mRNA analysis by PCR array using RPL19 as internal control. Each bar is the 
mean  SEM of eight observations. Bar head with asterisks (*) indicate that the data are 
significantly different from controls. The GATA3 mRNA expression was found to be 
enhanced in a 50 µg/mL of WYRE in both cell lines (Figure 8.1). Moreover, GATA3 
mRNA content relative to RPL19 was increased significantly only in MDA-MB-231 cells 
at 1 μM of 5-AZA. Other 5-AZA concentrations in MDA-MB-231 cells were unable to 
alter GATA3 mRNA content. Also, MCF-7 cells were irresponsive to any concentrations 




1.4 Expression of GATA3 protein  in MCF-7 and MDA-MB-231 cells 
 
 Cell lysates from MCF-7 and MDA-MB-231 cells were used for immunoblotting using 
polyclonal antibody specific for GATA3 and β- actin as loading control. Protein 
expression of GATA3 in MCF-7 cells was found to be higher than MDA-MB-231cells 

































Figure 9: Protein expression of GATA3 in MCF-7 cells was detected higher than MDA-
MB-231cells. P = positive control (GATA3 lysate from Santa Cruz Biotechnology, Dallas, 
TX)  MC=MCF-7 and MD=MDA-MB-231 cells.  
 
1.5 Effects of WYRE on global DNA methylation pattern of MCF-7 and MDA-MB-
231 cells.  
 
Global DNA methylation pattern as 5-mC was determined as 5’-methyl-2’-deoxycytidine 
(5MedCyd) content in the genomic DNA following a commercial ELISA kit protocols 
(Cell Biolabs). It was observed that 5-mC levels were identical in both cells (2232 72 
nM / 10 μg DNA in MCF-7 and 2349 59 nM/10 μg DNA in MDA-MB-231 cells). WYRE 
at 10μg/mL and 50μg/mL concentrations was able to increase the 5-mC content in 
MCF-7 cells significantly (5.02% and 9.27% increase over control, respectively). Other 
concentrations (25 and 35 μg/mL) did not reach statistical significance. In MDA-MB-231 
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cells, WYRE did not show any significant increase in the 5-mC content compared to 
controls (Figure 10.1). The genomic DNA was also used for 5-hydroxymethylcytosine (5-
hmC) analysis. It was observed that in MCF-7 cells 5-hmC content remained unaltered 
while in MDA-MB-231 cells 5-hmC levels were significantly decreased by all 
concentrations of WYRE used in this study (10-50 μg/mL) when compared with the 
corresponding controls (Figure 10.2).  
 
5MedCyd










































































Figure 10: Effect of WYRE on global DNA methylation of MCF-7 and MDA-MB-231 cells. 
Global DNA methylation was determined as 5-mC and 5-hmC by following a method 
developed by manufacturer (Cell Biolab). Cells were treated with WYRE (0-50 µg/mL) 
for 72 h. DNA was extracted by Trizol reagents and used for analysis.  Each bar is the 
mean SEM of four observations. Bar head with asterisks (*) indicate that the data are 
significantly different from controls. The 5-mC level was found to be significantly 
different from controls only in MCF-7 cells (50 μg/mL), however, 5-hmC level was 
significantly different in MDA-MB-231 cells (10-50 μg/mL). Figure 10.1= 5-mC and 
Figure 10.2= 5-hmC 
 
 
1.6 Effects of WYRE on DNMT1, DNMT3A, DNMT3B, TET1, TET2, and TET3 mRNA 
contents of MCF-7 and MDA-MB-231 cells.  
 
The quantitative mRNA analysis of three DNMT enzymes (DNMT1, 3A and 3B) and TET 
family of enzymes (TET1, TET2, and TET3) was done in WYRE-treated MCF-7 and 




contents of DNMT1, 3A, and 3B were increased in both cell lines in a concentration-
dependent manner. The increase was significant in MCF-7 cells treated with 50 µg/mL 
of WYRE whereas, a significant increase was observed in MDA-MB-231 cells treated 
with 25 and 50 μg/mL of WYRE as compared to controls (Figure 11). The TET1, TET2 
and TET3 mRNA contents in MCF-7 cells were remained unalter; however, MDA-MB-
















Figure 11:  Effect of WYRE on DNMT1, DNMT3A, and DNMT3B mRNA content of MCF-
7 and MDA-MB-231 cells. Total RNA was extracted by Trizol reagent and used for 
DNMT1, DNMT3A and DNMT3B  mRNA analysis by PCR array. RPL19 was used as 
internal control. Each bar is the mean  SEM of eight observations. Bar head with 
asterisks (*) indicate that the data are significantly different from controls. The mRNA 
expressions of these three genes were enhanced in a concentration-dependent manner 







































































































Figure 12:  Effect of wild yam root extract on TET1, TET2, and TET3 mRNA content of 





used for TET1, TET2, and TET3 mRNA analysis by PCR array. ACTB was used as 
internal control. Each bar is the mean  SEM of eight observations. Bar head with 
asterisks (*) indicate that the data are significantly different from controls. Figure 12.1= 
TET1; Figure 12.2= TET2; Figure 12.3= TET 3 
 
 
1.7 Effects of WYRE on the locus-specific DNA methylation pattern of GATA3 
promoters.  
 
The amplified GATA3 promoter is spanned 580 bp (-1994 to -2573 bp considering ATG= 
+1) and consists of thirty two 5’-CG-3’ and six 5’-CCGG-3’ sites which can be 
recognized by HpaII, however, it cannot be cleaved if the internal C (cytosine) is 
methylated. The HpaII isoschizomer MspI can also recognize 5’-CCGG-3’ and cleave 
the site irrespective of the methylation status of the internal C. If the outer C is 
methylated than neither of the enzymes (Msp1 or Hpa II) can recognize the 5’-CCGG-3’ 
site. Therefore, difference in the extent of fragmentation of genomic DNA between these 
two endonucleases indicates variation of methylation in 5’-CG-3’ sites. Our data showed 
that in both MCF-7 and MDA-MB-231 cells the amplified GATA3 DNA content in uncut 
(no endonuclease treatment) and HpaII digested genomic DNA are identical in control 
and WYRE-treated cells which indicate that the inner C in all six 5’-CCGG-3’ site of 
GATA3 promoter are methylated at this locus. Treatment of WYRE (50 μg/mL) is unable 
to alter methylation in these sites (inner Cs). However, we have observed significant 
variation when we compared the amplified DNA of uncut control and HpaII digested 
DNA with the DNA amplified from Msp1digested DNA. As Msp1 can recognize 5’-
CCGG-3’ sites irrespective of inner C methylation, we expect that the genomic DNA 
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amplification will either be neglible or undetectable. In both control and WYRE-treated 
MCF-7 cells, the amplified DNA of Msp1 digested genomic DNA was significantly lower 
than the amplified DNA obtained either from uncut or HpaII digested genomic DNA 
which also indicates that the outer C in all six 5’-CCGG-3’ site of GATA3 locus is not 
methylated and remained unaltered by WYRE (50 μg/mL). However, in MDA-MB-231 
cells, the amplified product of Msp1 digested genomic DNA in control cells was identical 
with uncut control, but significantly different from the DNA amplified by Hpa II digested 
genomic DNA. Therefore the methylation of outer C of 5’-CCGG-3’ sites of GATA3 in 
this locus is likely to be different in MDA-MB-231 cells than MCF-7 cells. In contrast, in 
WYRE treated cells the amplified DNA of Msp1 digested genomic DNA is significantly 
different (lower) from the amplified DNA of both uncut and Hpa II digested genomic DNA 
indicating demethylation in outer C of all the six 5’-CCGG-3’ sites of GATA3 locus exists 
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Figure 14: Effect of WYRE on GATA3 promoter analysis of MCF-7 and MDA-MB-231 
cells. Cells were treated with WYRE (0-50 µg/mL) for 72 h. DNA was extracted by Trizol 
reagents and used for promoter analysis. Genomic DNA was digested with buffer 



















specific primers. ACTB was used as internal control. The amplified PCR products were 
separated on 2% agarose gel (upper panel). GATA3 band is at 580 bp and ACTB band 
is at 283 bp region. U=amplified product of uncut (not digested with RE) genomic DNA, 
H= amplified product of HpaII digested genomic DNA, M= amplified product of Msp1 
digested genomic DNA. 500= 500 bp, 100= 100 bp. Distinct GATA3 and ACTB bands 
are observed in U and H lanes whereas in M lanes the GATA3 bands are either faint or 
absent in contrast to ACTB bands. The histogram (lower panel) is the GATA3 promoter 
methylation analysis of amplified genomic DNA obtained after RE digestion. Each bar is 
the mean SEM of four observations. Bar head with asterisks (*) indicate the data are 
significantly different from controls. Bar head with pound symbol (#) indicates that the 
data are significantly different from HpaII digested samples.  
 
 
2.1  Effects of dioscin and diosgenin on cell viability at 72 h   
 
 
We examined the effects of dioscin and diosgenin on the viability of MCF-7 and MDA-
MB-231 cells in vitro. The cells were treated with various concentrations of dioscin  and 
diosgenin  for 72 h and cell viability was determined by XTT method. It was observed 
that dioscin was able to decrease the cell viability at 72 h in a concentration-dependent 
manner with calculated IC50 of 3.85 and 2.07 μM for MCF-7 and MDA-MB-231 cells, 
respectively. Diosgenin was also able to decrease the cell viability at much higher 
concentrations than dioscin. Calculated IC50 of diosgenin were greater than 24.13 and 























































































































































Figure 14: Effect of dioscin and diosgenin on cell viabilities of MCF-7 and MDA-MB-231 
cells. Cells were treated with various concentrations of dioscin and diosgenin for 72 h. 




2.2  Effect of diosgenin and dioscin on GATA3  mRNA content 
 
 
Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with either 
diosgenin (0-24.14 µM) or dioscin (0-5.76 µM) and used for GATA3 mRNA analysis by 
PCR array. RPL19 was used as internal control. The GATA3 mRNA content were 
unaltered in MDA-MB-231 cells treated with diosgenin at all concentrations used in this 
study (2.41-24.14 µM) (Figure 15). However, mRNA expressions of GATA3 were 
enhanced at concentration of 5.76 µM of dioscin. Lower concentrations of dioscin (1.15-













































Figure 15: Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated 
with diosgenin (0-24.14 µM) and used for GATA3 mRNA analysis by PCR array. RPL19 
was used as internal control. The GATA3 mRNA content were remained unaltered in 
MDA-MB-231 cells treated with diosgenin at all concentrations used in this study (2.41-
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24.14 µM).  Each bar is the mean  SEM of eight observations. Bar head with asterisks 













































Figure 16: Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated 
with dioscin (0-5.76 µM) and used for GATA3 mRNA analysis by PCR array. RPL19 was 
used as internal control. The mRNA expressions of GATA3 were enhanced at a 
concentration of 5.76 µM of dioscin. Dioscin at 1.15-2.30 µM was unable to alter GATA3 
mRNA expression when compared with controls. Each bar is the mean  SEM of eight 






2.3 Dioscin enhances the GATA3 protein expression in MDA-MB-231 cells 
  
 
To validate the mRNA results, we did western blots using a polyclonal antibody specific 
for GATA3 on MDA-MB-231 cells treated with dioscin (1.15-5.76 µM). We also used 5- 
Aza which is a known demethylating agent and GATA3 lysate from Santa Cruz 
Biotechnology, Dallas, TX as positive controls.   Our results showed that GATA3 protein 
expression was enhanced in a concentration- dependent manner in MDA-MB-231 cells 























































Figure 17:  Representative figure showing the effect of dioscin on GATA3 protein 
expression in MDA-MB-231 cells by using a polyclonal antibody specific for GATA3 on 
MDA-MB-231 cells treated with dioscin (1.15-5.76 µM), 1 µM of 5-AZA and GATA3 
lysate from Santa Cruz Biotechnology, Dallas, TX as positive controls.   β- actin was 
used as loading control.  The data indicated that GATA3 protein expression was 
enhanced in MDA-MB-231 cells treated with dioscin (1.15-5.76 µM) and 5-AZA (1µM) 
compared with controls. DC=dioscin, 5-AZA= 5-Azacytidine, P= positive control (GATA3 
lysate from Santa Cruz Biotechnology, Dallas, TX)  
 
 
2.4  Dioscin enhances the GATA3 protein expression in both MCF-7 and  MDA-
MB-231 cells  
 
We next confirmed whether dioscin enhanced GATA3 protein expression in triple 
negative breast cancer cell line by comparing expression in MDA-MB-231 cells with 
MCF-7 cells which are known as ER+ and have higher GATA3 expression than MDA-
MB-231 cells.   Immunocytochemical analysis of GATA3 protein expression was used in 
MCF-7 cells (A-D) and MDA-MB-231 (E-H) cells. The cells were fixed in 4% PFA and 
stained with rabbit anti-GATA3 polyclonal antibody and counterstained by DAPI and 
examined by a confocal microscope LSM 510. A,E =control. B,F= cells treated with 5.76 
μM of dioscin. C,G = magnified to 40X of cells treated with 5.76 μM of dioscin. D,H= 
representative MCF-7 and MDA-MB-231 cell morphology. Both MCF-7 and MDA-MB-
231 cells after treating with dioscin showed increased the GATA3 protein expression 












Figure 18:    Immunocytochemical analysis of GATA3 protein expressed in 
MCF-7 cells (A-D) and MDA-MB-231 (E-H) cells. The cells were fixed in 4% 
PFA and stained with rabbit anti-GATA3 polyclonal antibody and 
counterstained by DAPI. Cells were examined by a confocal microscope 
LSM510. A,E =control. B,F= cells treated with 5.76 μM of dioscin. C,G = 
magnified to 40X of cells treated with 5.76 μM of dioscin. D,H= 
representative MCF-7 and MDA-MB-231 cell morphology. Both MCF-7 and 
MDA-MB-231 cells after treatment with dioscin increased the GATA3  protein 






2.5  Effect of dioscin on ZFPM2  mRNA expression in MCF-7 and MDA-MB-231 
cells  
 
Total RNA was extracted by Trizol reagent from MCF-7 and MDA-MB-231 cells treated 
with dioscin (0-5.76 µM) and used for ZFPM2 mRNA analysis by PCR array. RPL19 was 
used as internal control. The mRNA expression of ZFPM2 was enhanced significantly at 
a concentration of 5.76 µM of dioscin in both cell lines when compared with 
corresponding controls. Other concentrations of dioscin (1.15-2.30 µM) remained 



























































Figure 19: Effect of dioscin on ZFPM2  mRNA expression in MCF-7 and MDA-MB-231 
cells. Total RNA was extracted by Trizol reagent from MCF-7 and  MDA-MB-231 cells 
treated with dioscin (0-5.76 µM) and used for ZFPM2 mRNA analysis by PCR array. 
RPL19 was used as internal control. The mRNA expression of ZFPM2 was enhanced at 
a concentration of 5.76 µM of dioscin in both cell lines.  Lower concentrations of dioscin 
(1.15-2.30 µM) were unable to alter ZFPM2 mRNA content in both cell lines. Each bar is 
the mean  SEM of eight observations. Bar head with asterisks (*) indicate that the data 
are significantly different from controls.  
 
2.6 Effect of dioscin on CDH1 (E-Cadherin)  mRNA expression in MCF-7 and MDA-
MB-231 cells  
 
 
Total RNA was extracted by Trizol reagent from MCF-7 and MDA-MB-231 cells treated 
with dioscin (0-5.76 µM) and used for CDH1 mRNA analysis by PCR array. RPL19 was 
used as internal control. The mRNA expressions of CDH1 were enhanced at a 
concentration of 5.76 µM of dioscin in both cell lines.  Lower concentrations of dioscin 

























































Figure 20: Effect of dioscin on CDH1 mRNA expression in MCF-7 and MDA-MB-231 
cells. Total RNA was extracted by Trizol reagent from MCF-7 and MDA-MB-231 cells 
treated with dioscin (0-5.76 µM) and used for CDH1 mRNA analysis by PCR array. 
RPL19 was used as internal control. The mRNA expression of CDH1 was enhanced at 
a concentration of 5.76 µM of dioscin in both cell lines.  Lower concentrations of dioscin 
(1.15-2.30 µM) were unable to alter CDH1 mRNA content in both cell lines. Each bar is 
the mean  SEM of eight observations. Bar head with asterisks (*) indicate that the data 
are significantly different from controls. 
 
 
2.7 Effect of dioscin on MMP9 mRNA content in MDA-MB-231 cells  
 
 
Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with dioscin 
(0-5.76 µM) and used for MMP9 mRNA analysis by PCR array. RPL19 was used as 
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internal control. The mRNA expression of MMP9 was suppressed at a concentration of 
2.30 µM of dioscin. Lower concentration of dioscin at 1.15 µM and higher concentration 
of dioscin (at 5.76 µM) were unable to alter MMP9 mRNA content when compared with 
corresponding controls (Figure 21). 
 








































Figure 21: Effect of dioscin on MMP9 mRNA expression in MDA-MB-231 cells. Total 
RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with dioscin (0-
5.76 µM) and used for MMP9 mRNA analysis by PCR array. RPL19 was used as 
internal control. The mRNA expression of MMP9 was decreased in only concentration of 
dioscin 2.30 µM. Each bar is the mean  SEM of eight observations. Bar head with 






2.8 Effect of dioscin on Vimentin mRNA expression in MDA-MB-231 cells 
 
 
Total RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with dioscin 
(0-5.76 µM) and used for VIM mRNA analysis by PCR array. RPL19 was used as 
internal control. The mRNA expressions of VIM were reduced at a concentration of 2.30 
and 5.76 µM of dioscin. Lower concentration of dioscin at 1.15 µM was unable to alter 
VIM mRNA content. (Figure 22) 
 
 






































Figure 22: Effect of dioscin on Vimentin mRNA expression in MDA-MB-231 cells Total 
RNA was extracted by Trizol reagent from MDA-MB-231 cells treated with dioscin (0-
5.76 µM) and used for VIM mRNA analysis by PCR array. RPL19 was used as internal 
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control. The mRNA expressions of VIM were  reduced  at a concentration of 2.30 and 
5.76 µM of dioscin.  Lower concentration of dioscin at 1.15 µM was unable to alter VIM  
mRNA content. Each bar is the mean  SEM of eight observations. Bar head with 
asterisks (*) indicate that the data are significantly different from controls. 
 
 
2.9 Effects of dioscin on MCF-7 and MDA-MB-231 cell viability after 24 h of 
treatment  
  
We examined the effects of dioscin on viability of MCF-7 and MDA-MB-231 cells in vitro 
after 24h of treatment. The cells were treated with various concentrations of dioscin (0-
23.03 μM) for 24 h and cell viability was determined by XTT method. It was observed 
that dioscin was able to decrease the cell viability at 24 h in a concentration-dependent 
manner with calculated IC50 of 13.70 and 6.77 μM for MCF-7 and MDA-MB-231 cells, 























































































Figure 23: Effect of dioscin on viabilities of MCF-7 and MDA-MB-231 cells after 24h of 
treatment. Cells were treated with various concentrations of dioscin (0-23.03 μM) for 24 
h. Cell viability is presented as mean ± SEM of eight independent experiments. Bar 
head with asterisks (*) indicate that the data are significantly different from controls. 
 
2.10  Dioscin inhibit migration in MDA-MB-231 cells  
 
 
After MDA-MB-231 cells incubated with different concentrations of dioscin (0.58, 1.15, 
2.30 and 5.76 µM) for 12h, 18h and 24h, dioscin could suppress migration of MDA-MB-
231 cells in both concentration- and time- dependent manner. These results revealed 
that dioscin inhibited the motility of MDA-MB-231 cells significantly when compared with 
corresponding controls (Figure 24-29). 











Figure 24: Effect of dioscin on migration of MDA-MB-231 cells. Cell monolayers were 
scraped by sterile micropipette tip and the cells were treated with various concentrations 
of dioscin for 24 h. Cells migrated to wounded region over time and  were photographed 
(4X magnification).  Photographs were taken at 0, 12, 18 and 24h and analyzed by 
WIMasis image analysis program by IBIDI®. 
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Figure 25: Effect of dioscin on migration of MDA-MB-231 cells. Cell monolayers were 
scraped by sterile micropipette tip and the cells were treated with various concentrations 
of dioscin (1.15, 2.30 and 5.76 µM). Cells migrated to wounded region were 
photographed (4X magnification) at 0h and analyzed by WIMasis image analysis 
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Figure 26: Effect of dioscin on migration of MDA-MB-231 cells. Cell monolayers were 
scraped by sterile micropipette tip and the cells were treated with various concentrations 
of dioscin (1.15, 2.30 and 5.76 µM) for 12 h (A) cells migrated to wounded region were 
photographed (4X magnification) at 12h and analyzed by WIMasis image analysis 
program by IBIDI®  (B) The scratch area of cell cultures were quantified from three 
independent experiments. Data are presented as mean ± SEM of three independent 






































Figure 27: Effect of dioscin on migration of MDA-MB-231 cells. Cells monolayers were 
scraped by sterile micropipette tip and the cells were treated with various concentrations 
of dioscin (1.15, 2.30 and 5.76 µM) for 18 h (A) cells migrated to wounded region were 
photographed (4X magnification) at 18h and analyzed by WIMasis image analysis 
program by IBIDI®  (B) The scratch area of cell cultures were quantified from three 
independent experiments. Data are presented as mean ± SEM of three independent 
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Figure 28: Effect of dioscin on migration of MDA-MB-231 cells. Cells monolayers were 
scraped by sterile micropipette tip and the cells were treated with various concentrations 





photographed (4X magnification) at 24h and analyzed by WIMasis image analysis 
program by IBIDI® (B) The scratch area of cell cultures were quantified from three 
independent experiments. Data are presented as mean ± SEM of three independent 
experiments. Bar head with asterisks (*) indicate that the data are significantly different 
from controls. 
 

































Figure 29: Effect of dioscin on migration of MDA-MB-231 cells. Cells monolayers were 
scraped by sterile micropipette tip and the cells were treated with various concentrations 
of dioscin (1.15, 2.30 and 5.76 µM) for 24 h (A) cells migrated to wounded region were 
photographed (4X magnification) and analyzed by using WIMasis image analysis by 
IBIDI®  (B) The scratch area of cell cultures were quantified from three independent 
experiments. Data are presented as mean ± SEM of three independent experiments. 








2.11 Effect of cellular migration in MCF-7 and MDA-MB-231 cells 
 
Cell migration was determined by using Boyden chambers with an 8 micron 
polyethylene terephthalate (PET) membrane and detected the quantity of cell migration 
by using fluorescein technique. MDA-MB-231 cells which are triple negative breast 
cancer cells had higher migration activity when compared with MCF-7 cells which are 





















Figure 30:  Comparison of cell migration between MCF-7 and MDA-MB-231 cells. It was 
observed that the migration of MDA-MB-231 cells was significantly higher when 
compared with MCF-7 cells. Data are presented as mean ± SEM of twelve independent 








2.12 Effect of dioscin on cellular migration in MCF-7 and MDA-MB-231 cells 
 
 
To validate the anti migration effect of dioscin in MDA-MB-231cells and analyzed the 
cellular migration of MCF-7 cells, we employed Boyden chambers with an 8 micron 
polyethylene terephthalate (PET) membrane and detect the quantity of cell invasion by 
using fluorescein technique (Trevigen, Gaithersburg, MD) in both cell lines. The results 
showed that dioscin could inhibit the cell migration at 5.76 µM in both MCF-7 and MDA-









































Figure 31:  Effect of dioscin on cellular migration in MCF-7 and MDA-MB-231cells. 
Dioscin 5.76 µM could suppress migration of MDA-MB-231 and MCF-7 cells when 
compared with corresponding controls. Data are presented as mean ± SEM of six 
independent experiments. Bar head with asterisks (*) indicate that the data are 
significantly different from controls. 
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2.13  Effect of dioscin on cellular invasion in MCF-7 and MDA-MB-231 cells  
 
 
To analyzed the effect of dioscin on cellular invasion of MCF-7 and MDA-MB-231 cells, 
we employed Boyden chambers with an 8 micron polyethylene terephthalate (PET) 
membrane that coated with Basement membrane Extract (BME) and detected the 
quantity of cell invasion by using fluorescein technique (Trevigen, Gaithersburg, MD) in 
both cell lines.  The results showed that dioscin could suppress invasion of MDA-MB-
231 and MCF-7 cells across basement membrane coated filter. Treatment with dioscin 
of 5.76 µM inhibited 65% and 60% of cell invasion in MDA-MB-231 and MCF-7 cells, 
respectively. The results indicated that dioscin markedly inhibited invasion of both cell 
















































Figure 32:  Effect of dioscin on cellular invasion in MCF-7 and MDA-MB-231cells. 
Dioscin suppressed invasion of MDA-MB-231 and MCF-7 cells across basement 
membrane coated filter. Treatment with dioscin of 5.76 µM inhibited 65% and 60% of 
cell invasion in MDA-MB-231 and MCF-7 cells, respectively. Data are presented as 
mean ± SEM of six independent experiments. Bar head with asterisks (*) indicate that 






Although efforts to develop drugs for breast cancer treatment have yielded many 
successes, breast cancer remains the second leading cause of cancer death in 
American women (Amatori et al. 2010). This high incidence of mortality highlights the 
need for new therapeutics. The mechanisms associated with breast cancer are genetic 
alterations including specific gene amplifications, deletions, point mutations, 
chromosome rearrangementd and aneuploidy; however, breast cancer is also driven by 
epigenetic mechanism (Dworkin, Huang, and Toland 2009a, Jovanovic et al. 2010, 
Kress et al. 2010). These epigenetic alterations do not affect the primary DNA sequence 
and occur through three mutually interacting events, namely DNA methylation, histone 
modifications and nucleosomal remodeling. These events modulate chromatin structure, 
and in turn activate or silence gene expression (Lo and Sukumar 2008). Epigenetic 
therapy is potentially useful because epigenetic defects are thought to be more easily 
reversible when compared with genetic defects (Kristensen, Nielsen, and Hansen 2009). 
Moreover, in breast cancer cells, a variety of genes participating in different cellular 
processes such as cell cycle inhibition (p16RASSF1A), DNA repair (BRCA1), 
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proapoptotic processes (HOX5, TMS1), metabolic events (GSTP1), cell adhesion and 
metastatic processes (CDH1, CDH13) are affected by epigenetic modifications 
(Widschwendter and Jones 2002). Analysis of both primary invasive breast cancer and 
normal breast samples by genome-wide methylation array technology identified higher 
frequency of methylation in ER+ tumors (5264 loci) compared to ER- tumors (3112 
loci)(Fackler et al. 2011, Connolly and Stearns 2012). Also several other studies in 
breast cancer cells identified genes (APC, BINI, BMP6, BRACA1, CST6, ESRb, GSTP1, 
PI6, P21, and TIMP3) which are functionally silent due to inappropriate promoter 
hypermethylation (Radpour R et al. 2009). A recent study in ER+ and ER- breast cancer 
cell lines identified genes including GATA3 which were hypermethylated and silent in 
ER- cells but hypomethylated and active in ER+ cells (Sun, Asmann, et al. 2011). One 
new potential source for therapeutics of breast cancer is plants used in traditional 
Chinese medicine (TCM) which have been successfully used for treatment of many 
diseases, including cancer (Medina-Franco et al. 2011, Newman 2008). Studies of 
natural products such as tea polyphenols, genistein, diadzein, and equol indicate that 
these compounds either alone or in combination have the potential to be used as 
therapeutic agents in breast cancer (Fang et al. 2003, Newman 2008). Therefore, we 
evaluated the efficacy of WYRE as a potential modulator of DNA methylation and 
function by using both ER+ (MCF-7) and ER- (MDA-MB-231) cells and concentrated on 
GATA3 gene which is considered as an important marker of breast cancer progression 
(Tominaga et al. 2012, Chou et al. 2013).  
Our data indicated that WYRE was able to increase the expression of GATA3 mRNA in 
both ER+ (MCF-7) and ER- (MDA-MB-231) human breast cancer cells in a 
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concentration-dependent manner (Figure 7).  Also, WYRE was able to reduce in vitro 
cell viability of both cell lines. Moreover, MCF-7 cells have approximately 10-fold higher 
GATA3 mRNA copy number (Figure 7) and 4-fold higher GATA3 protein level than MDA-
MB-231 cells (Figure 9).  As the response of both cell lines to WYRE enhanced in 
GATA3 mRNA expression, we anticipate that WYRE might be able to alter the 
methylation status in GATA3 gene in both cell lines. A recent study in ER+ and ER- 
breast cancer cell lines identified GATA3 gene, which were hypermethylated and silent 
in ER- cells but hypomethylated and active in ER+ cells (Sun, Asmann, et al. 2011, 
Chou et al. 2013, Hoch et al. 1999, Yan et al. 2010, Yoon et al. 2010).  There are reports 
that in breast cancer cells, GATA3 mRNA expression is ERα-dependent, the expression 
of this gene was observed only in ER+ cells (MCF-7 and BT474) but not in ER (Licata 
et al. 2010, Hoch et al. 1999, Yan et al. 2010). Therefore, we predict that, WYRE is able 
to enhance GATA3 mRNA expression either by up-regulating ER as in ER+ cells or by 
modulating hypermethylated GATA3 gene promoter in MDA-MB-231 cells. Moreover, 
our data on DNMT inhibitor, 5-AZA, which is a nucleoside analogue of DNMT inhibitor 
approved by FDA for the treatment of myelodysplastic syndrome, showed that GATA3 
mRNA expression relative to RPL19 was increased significantly only in MDA-MB-231 
cells at 1 μM of 5-AZA and  MCF-7 cells were found to be irresponsive to any 
concentrations of 5-AZA (250-1000 nM) (Figure 8.2). Our data is similar to the study of 
Pryzbylkowski P et.al 2008, which showed that treatment of MDA-MB-231 cells with 5-
AZA at 2.5 M, for 96h resulted in re-expression of ER mRNA content (Pryzbylkowski, 
Obajimi, and Keen 2008). GATA3 expression in breast tumors highly correlated with the 
expression of estrogen receptor alpha (ER1). The highest expression of GATA3 and 
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ER1 is associated with the most favorable survival outcomes. Even though MCF-7 cells 
were irresponsive to any concentrations of 5-AZA (250-1000 nM), from this study also 
claimed that after treatment 5-AZA with MCF-7 cells resulted in decreased ER mRNA 
expression due to decrease stability through altered subcellular localization of RNA 
binding protein, HuR.  Therefore, control of mRNA stability may involve (Pryzbylkowski, 
Obajimi, and Keen 2008).  As GATA3 gene in ER breast cancer cells (MDA-MB-231 
cells) remained silent due to inappropriate promoter methylation (hypermethylation) 
(Sun, Asmann, et al. 2011, Chou et al. 2013, Hoch et al. 1999, Yan et al. 2010, Yoon et 
al. 2010), we predict that WYRE is able to reactivate GATA3 gene expression in MDA-
MB-231 cells by altering the methylation status of GATA3 promoters in a mechanism 
which is probably different from 5-AZA (Peedicayil 2006). Before analyzing GATA3 
promoter methylation at specific regions, we investigated the effects of WYRE on global 
DNA methylation in these cell lines, because the genome of cancer cells displays global 
hypomethylation in one hand, and local gene-specific hypermethylation on the other 
(Sharma, Kelly, and Jones 2010). Global DNA methylation was determined as 5-
methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC). Although 5-mC is the 
predominant epigenetic marker in mammalian genome, 5-hmC is a newly discovered 
epigenetic modification that is presumably generated by oxidation of 5-mC by ten-
eleven-translocation (TET) family of cytosine oxygenases (Chen et al. 2013). The 
conventional bisulfite treatment is unable to differentiate 5-mC from 5-hmC, we 
therefore used ELISA-based techniques (Cell Biolabs, San Diego, CA). In this method, 
5-mC is detected as 5'-methyl-2'-deoxycytidine (5MedCyd) content of the genomic DNA. 
Our data indicated a cell-line specific alteration in the global DNA methylation pattern in 
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these two cell lines (Figure 10). In MCF-7 cells, 5-mC was found to increase 
significantly by WYRE only in 50 µg/mL concentrations (Figure 10.1) which indicates a 
possibility of hypermethylation but 5-hmC remained unaltered (Figure 10.2). On the 
other hand, in MDA-MB-231 cells, 5-mC remained unaltered (Figure 10.1), but 5-hmC 
reduced significantly in all of the concentrations of WYRE used in this study (Figure 
10.2) indicating a probability of hypomethylation. Our data are to some extent identical 
with the DNMT inhibitor DAC, which is, at 8 µM concentration,  able to cause hypo 
methylation in docetaxel-resistant MCF-7 and MDA-MB-231 cells after 24 h treatment 
even though the data are significantly different only in MDA-MB-231 cells (Kastl, Brown, 
and Schofield 2010).  Although  we are unable to explain the mechanism (s) properly, 
because 5-hmC modifications are known to prevalent in DNA of embryonic stem cells 
and neurons (Kriaucionis and Heintz 2009, Tahiliani et al. 2009) and 5-hmC contents 
are reduced in the carcinomas of prostate, breast, liver, lung, pancreas, and colon 
(Yang et al. 2013), our data indicate that WYRE like other DNMT inhibitors has the 
potential to modulate global DNA methylation which is specific to the ER sensitivity 
breast cancer cell lines. Moreover, these alterations in global DNA methylation in MCF-7 
(5-mC) and MDA-MB-231 (5-hmC) cells by WYRE are enabling us to analyze DNMT 
and TET enzymes at the message level. 
DNMT family of enzymes catalyze the covalent addition of a methyl group at the carbon 
5 position of a CpG dinucleotide (5-mC) into the genome (Haffner et al. 2011, Kudo et al. 
2012) and TET family of enzymes oxidized 5-mC to 5-hmC (Chen et al. 2013, Tan and 
Shi 2012, Hashimoto et al. 2012, He et al. 2011, Ito et al. 2011).   In human genome, 
five DNMT enzymes have been identified; among them two de novo methyltransferases 
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(DNMT3A and DNMT3B) and the maintenance methyltransferase DNMT1 are the key 
regulators of DNA methylation (Bestor 2000, Okano et al. 1999). Mammalian cells 
express three TET genes, TET1, TET2, and TET3 (He et al. 2011) and TET family of 
enzymes is capable of catalyzing the sequential oxidation of 5-mC to 5-hmC, 5-
formylcytosine (5-fC), and finally 5-carboxylcytosine (5-caC) (Bestor 2000, Kriaucionis 
and Heintz 2009, Tahiliani et al. 2009, Ito et al. 2011).  5-caC can be recognized and 
cleaved by thymine-DNA glycosylase that restore unmethylated cytosine via base-
excision repair (BER) system (Ito et al. 2011 ). Thus, active DNA demethylation may be 
achieved through a multistep oxidation of 5-mC with the generation of various forms of 
intermediates (Chen et al. 2013). Therefore, analyses of DNMT and TET enzymes are 
necessary. It was observed that mRNA contents of DNMT1, 3A, and 3B were increased 
in both cell lines in a concentration-dependent manner. The increase was significant in 
MCF-7 cells treated with 50 µg/mL of WYRE whereas, a significant increase was 
observed in MDA-MB-231 cells treated with 25 and 50 μg/mL of WYRE as compared to 
controls (Figure 11).  Moreover, TET mRNA analysis indicates that in MDA-MB-231 cells 
treated with 50 μg/mL of WYRE, TET3 mRNA expression significantly enhanced (Figure 
12).  Although the specific reason of enhanced DNMT mRNAs in MDA-MB-231 cells by 
WYRE is unknown to us, alteration in DNMT enzyme activity should be reflected on 
specific gene methylation as well as in global DNA methylation. The present data also 
showed that 5-hmC was dramatically reduced by WYRE in MDA-MB-231 cells (Figure 
10.2) which may create a necessary stimulation to DNMT genes to become activate and 
to synthesize DNMT mRNAs. Moreover, TET mRNA analysis indicates that MDA-MB-
231 cells treated with 50 µg/mL of WYRE compared with controls TET3 significantly 
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increased. These data support that the reduced level of 5-hmC may increase TET3 
mRNA to get the MDA-MB-231 cell ready for 5-hmC syntheses and further converted to 
other intermediates.  In contrast, in MCF-7 cells increased in 5-mC and no alteration in 
5-hmC, made DNMT genes to become unresponsive to alter GATA3 promoter 
methylation. However, in docetaxel-resistant MCF-7 and MDA-MB-231 cells, the DNMT 
inhibitor DAC (8 M, 24 h) altered DNMT enzyme mRNA (DNMT1, 3A and 3B) 
expression in a cell line specific manner; increase in MCF-7 cells and decrease in MDA-
MB-231 cells (Kastl, Brown, and Schofield 2010). Further studies related to DNMT and 
TET proteins or enzymes would be required to understand the possible mechanism (s) 
played by TET (or to explain these results).  
As mentioned earlier, the genome of cancer cells displays global DNA hypomethylation 
on one hand, but local gene-specific hypermethylation on the other(Sharma, Kelly, and 
Jones 2010). As the expression of GATA3 mRNA is dependent on the methylation 
status on the promoter, we therefore focused on GATA3 promoter at a specific locus by 
applying RE techniques (Iida et al. 2006, Oakeley 1999). The amplified GATA3 fragment 
is spanned 580 bp and consists of thirty-two 5'-CG-3' and six 5'-CCGG-3' sites. We 
digested the genomic DNA with HpaII and Msp1 RE and amplified with GATA3 gene-
specific primers. The data were normalized against ACTB (Figure 13). Our data indicate 
that in MCF-7 cells all six 5'-CCGG-3' sites in GATA3 promoter are methylated only at 
inner C. Moreover, WYRE has no significant effect in altering methylation of either inner 
or outer C in these regions. However, in MDA-MB-231 cells methylation of inner C 
appears to be identical with MCF-7 cells (all methylated) but some MDA-MB-231 cells 
the outer C methylation status seems to be different from MCF-7 cells. Treatment of 
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WYRE (50 μg/mL) is able to demethylate outer C in 5'-CCGG-3' sites in these cells 
suggesting the potential of WYRE to demethylate GATA3 gene promoter at specific 
region.  
Taken together, our data indicate that WYRE is able to inhibit both ER+ and ER cell 
viability in a concentration-dependent manner and activates GATA3 mRNA expression 
with an alteration in global DNA methylation pattern. Although there could be other 
mechanisms that can reduce cell viability, the response of ER- MDA-MB-231 cells to 
WYRE is more pronounced than ER+ MCF-7 cells probably due to the difference in 
methylation status of target genes among these two cell lines. GATA3 promoter analysis 
at specific region is unable to demonstrate any dramatic demethylating effect of WYRE 
at 5'-CCGG-3' sites with regard to inner C. Demethylation by WYRE in outer C or Cs in 
other location of the promoter cannot be ruled out.   
We next focused on compounds, which were isolated from WYRE (NCNPR No. 9800) 
whether capable of selective upregulating GATA3 expression would demonstrate 
anticancer activity, specially increased differentiation and decrease invasiveness. The 
components of WYRE belonging to steroidal saponins and sapogenins are found to be 
noncarcinogenic (2004). To our knowledge, fourteen steroidal saponins, two flavan-3-ol 
glycosides and fourteen diarylheptanoids have been reported from wild yam (Figure 33, 
34) (Ali, Smillie, and Khan 2013, Dong et al. 2007, Hayes et al. 2007, Sautour, 
Miyamoto, and Lacaille-Dubois 2006, Yoon et al. 2010); among them diosgenin and 
dioscin exhibits anticancer activity (Jagadeesan et al. 2012). Therefore, we employed 





Figure 33: Base peak chromatograms of the D. villosa (NCNPR #9800) extracts 
analyzed using UHPLC-QToF-MS in positive ESI mode: dioscoreavilloside A (1),  
dioscoreavilloside B (2), parvifloside (3), protodeltonin (4), protodioscin (5), protobioside 
(6), huangjiangsu A (7), pseudoprotodioscin (8), 25(R)-dracaenoside G (9), 
zingiberensis saponin I (10), deltonin (11), dioscin (12), progenin III (13), and diosgenin 
(14) (Ali, Smillie, and Khan 2013) 
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Figure 34: Structures of compounds isolated from WYRE (NCNPR#9800)(Ali, Smillie, 





Our data showed that dioscin and diosgenin were able to reduce in vitro cell viability of 
both ER+ (MCF-7) and ER (MDA-MB-231) human breast cancer cells (Figure 14). Also, 
dioscin (IC50= 3.85 and 2.07 µM in MCF-7 and MDA-MB-231cells, respectively) is more 
potent than diosgenin (IC50 > 24.13 and 20.10 µM in MCF-7 and MDA-MB-231cells, 
respectively) in both cell lines (Figure 14). Moreover, our study has identified a key 
mechanism for GATA3 induced inhibition of metastatic propensity of Basal Triple- 
Negative Breast Cancer (BTNBC), an aggressive form of breast cancer with poor 
prognosis. We have demonstrated that only dioscin at 5.76 µM could induce GATA3 
mRNA expression in MDA-MB-231 cells (Figure 16). To validate the mRNA result, we 
analyzed GATA3 protein expression by using a polyclonal antibody specific for GATA3 
and our results showed that GATA3 protein level was enhanced in a concentration- 
dependent manner in MDA-MB-231 cells treated with dioscin 1.15-5.76 µM. We have 
also used 5-AZA (a known demethylating agent) for comparison. Our data indictaed that 
5-AZA at 1µM was able to increase GATA3 protein in MDA-MB-231 cells (Figure 17).  
The expression of GATA3 protein in MCF-7 and MDA-MB-231 cells were studied by 
visual fluorescence probe and observed under confocal microscope LSM 510 (Figure 
18). Our data demonstrated that within control groups MCF-7 cells have higher GATA3 
protein expression than MDA-MB-231 cells and dioscin enhanced the expression of 
GATA3 protein in both cell lines. Because of this, some MDA-MB-231 cells after 
treatment with dioscin at 5.76 µM altered their morphology from spindle- shaped tumor 
cells to epithelium- like in MCF-7 cells. These two distinct phenotypes are keenly 
associated with cell invasiveness and noninvasiveness, respectively. Our result is 
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similar to previous studies which showed that MDA-MB-231 cells expressed ectopic 
GATA3 when engineered with the full-length GATA3 gene by a retroviral infection 
system. These cells resembled the expression pattern of MCF-7 cells and displayed an 
epithelial phenotype identical to MCF-7 cells, being cuboidal-like and aggregated (Chu 
et al. 2012, Yan et al. 2010) (Figure 18).  From these results prompted us to analyze the 
effect of dioscin on regulator and downstream gene of GATA3. ZFPM2 gene encodes 
the Zinc Finger Protein ZFPM2 is a widely expressed member of the FOG family of 
transcription factors (Holmes et al. 1999, Svensson et al. 1999). The family members 
modulate the activity of GATA family proteins, which are important regulators in 
mammals. It has been demonstrated that the protein can both activate and down-
regulate expression of GATA-target genes (Holmes et al. 1999, Svensson et al. 1999). 
Our data found that dioscin at 5.76 µM increased the expression of ZFPM2 mRNA in 
both cell lines (Figure 19). GATA3 as a transcription factor binds with high affinity to 
consensus GATA or GATA-like motifs located in promoter region by which it 
transactivates gene expression. The study of Yan et al, 2010 showed that GATA3 
functions to up- regulate E-Cadherin expression through binding its motifs located in E-
Cadherin promoter (Yan et al. 2010). Moreover, E- Cadherin is a tumor suppressor gene 
(Semb and Christofori 1998), which is encoded by the CDH1 gene (Huntsman and 
Caldas 1998).  Loss of E-cadherin function or expression has been implicated in 
cancer progression and metastasis (Yan et al. 2010, Polyak and Weinberg 2009).  E-
cadherin downregulation decreases the strength of cellular adhesion within a tissue, 
resulting in an increase in cellular motility. This in turn may allow cancer cells to cross 
the basement membrane and invade surrounding tissues (Yan et al. 2010, Polyak and 
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Weinberg 2009).  Our data showed that dioscin could up regulated of E-Cadherin 
mRNA expression at 5.76 µM in both cell lines (Figure 20). These results from both 
regulator (ZFPM2) and downstream genes (CDH1) of GATA3 were correlation to GATA3 
expression effect by dioscin.  Moreover, cancer metastasis also requires migration of 
cancer cells. During cell migration, pericellular proteolysis of extracellular matrix (ECM) 
is important for cell protrusion. The proteolytic degradation of ECM mediated by 
extracellular proteases such as Matrix Metallopeptidases (MMPs) is required for breast 
cancer cells migration and invasion. Therefore, we next investigated the effect of dioscin 
on Matrix Metallopeptidase 9 (MMP9) and Vimentin (VIM) in MDA-MB-231 cells.  MMP 
family are involved in the breakdown of ECM  in both normal physiological processes, 
such as embryonic development ,angiogenesis, bone development, wound healing, and 
cell migration, and  in pathological processes, such as arthritis and metastasis 
(Vandooren, Van den Steen, and Opdenakker 2013).  MMP9 can be also involved in the 
development of several human malignancies including breast cancer, as degradation of 
collagen IV in basement membrane and ECM facilitates tumor progression such as 
invasion, metastasis, and angiogenesis (Groblewska et al. 2012). Another biomarker 
gene vimentin is a type III intermediate filament (IF) protein that is expressed 
in mesenchymal cells.  Because of this, vimentin is often used as a marker of 
mesenchymally-derived cells or cells undergoing an epithelial-to-mesenchymal 
transition (EMT) during both normal development and metastatic progression (Leader et 
al. 1987, Ulirsch et al. 2013). Our data showed that dioscin suppressed MMP9 mRNA 
expression only at concentration of 2.30 µM (Figure 21) but inhibited VIM mRNA 
expression at 2.30 and 5.76 µM of dioscin in MDA-MB-231 cells (Figure 22) which is 
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similar to a previous study that indicated the expression of GATA3 is positively related to 
elevated E-cadherin, but decreased vimentin, N-cadherin and MMP-9, which suggests 
that GATA3 may drive the invasive breast cancer cells to undergo the reversal of 
epithelial-mesenchymal transition (Yan et al. 2010).  Furthermore, we employed wound-
healing assay, which is simple and inexpensive to determine if dioscin could inhibit 
tumor cell migration in MDA-MB-231 cells. Our results demonstrated that dioscin had 
inhibitory effect on migration of MDA-MB-231 cells in both concentration- and time- 
dependent manner (Figure 24-29).  We also used Boyden chambers with an 8 micron 
polyethylene terephthalate (PET) membrane and detect the quantity of cell migration by 
using fluorescein technique by following the instruction provided by manufacturer 
(Trevigen, Gaithersburg, MD) in both MCF-7 and MDA-MB-231 cells. Our data showed 
that MDA-MB-231 cells which are BTNBC had higher migration activity when compared 
with MCF-7 cells which are ER+ and exhibit higher expression of GATA3 gene (Figure 
30). There are many studies indicated that MDA-MB-231 cells are invasive breast 
cancer cells due to low expression of GATA3; this correlated with a poorer outcome 
related to high tumor grade (poorly differentiated or undifferentiated), larger tumor size, 
and short disease –free survival. On the other hand MCF-7 cells which are ER+, GATA3 
positive and early stage well differentiated (non invasive) breast cancer had a very 
favorable prognosis. (Amatori et al. 2010, Kouros-Mehr et al. 2008, Kouros-Mehr et al. 
2006, Ordway et al. 2007, Yan et al. 2010, Yoon et al. 2010). Moreover, to see the effect 
of dioscin on cellular migration, we then treated MCF-7 and MDA-MB-231 cells with 
various concentration of dioscin (1.15-5.76 µM) and our data demonstrated that not only 
MDA-MB-231 cells had inhibitory effect on migration by dioscin at 5.76 µM, but also 
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MCF-7 treated with 5.76 µM of dioscin suppressed cell migration (Figure 31).  We also 
employed the same experiment but coated PEP membrane with BME for cell invasion 
study. Our results showed that dioscin at 5.76 µM had similar effect on cell invasion and 
cell migration in both cell lines. Moreover, treatment of dioscin at 5.76 µM inhibited 65% 
and 60% of cell invasion in MDA-MB-231 and MCF-7 cells, respectively (Figure 32). 
This result showed that MDA-MB-231 cells treated with dioscin at the same 
concentration had a little higher effect of inhibited invasion than MCF-7 cells.  Our data 
indicated that dioscin markly inhibited migration and invasion in both breast cancer cell 
lines. Importantly, increasing GATA3 expression in low expression MDA-MB-231 breast 
cancer cells led to cancer cells differentiating and decreased their invasion potential 
could be more advantage in women who have BTNBC that present very unfavorable 





We concluded that WYRE alter DNA methylation pattern on the promoter region 
of GATA3 gene showing demethylating activity of GATA3 gene in MDA-MB-231 cells. 
We also demonstrated the inhibitory effect of dioscin, which isolated from WYRE on 
proliferation, migration and invasion of MDA-MB-231 cells. Thus, dioscin could be a 
potential agent that suppressed breast cancer metastasis in BTNBC via up regulating 
GATA3 and E-Cadherin but inhibiting MMP9 and Vimentin.   Moreover, investigating the 
therapeutic potential and pharmacodynamic property of dioscin In vivo is imperative. 
These findings reveal a new therapeutic potential for dioscin on anti-metastatic therapy 
and in future this compound may be able to offer an efficacious adjuvant therapy to 
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